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Rationale: Infertility is the inability to conceive following 12 months of 
unprotected intercourse and affects 20% of couples worldwide. In vitro fertilisation 
(IVF) therapy has become more common in recent times. In mice, IVF associates 
with glucose intolerance. In humans, there is controversy regarding possible 
deleterious effects of IVF hormones in pregnancy, including worsening of 
metabolic, diabetogenic and inflammatory status.  
Objectives: To explore effects of IVF therapy in pregnancy on glucose and lipid 
homeostasis, and other metabolic and inflammatory parameters. To explore early 
predictors of onset of gestational diabetes mellitus (GDM), including whether use 
of IVF therapy may hasten the onset of GDM. 
Methodology: Adult non-diabetic women (n=275), BMI: 18.5-38kg/m2, age 
≤39years were recruited (n=158 pregnant, 117 non-pregnant). Collection of blood 
samples occurred throughout IVF cycle: baseline, 2, 4 and 12 weeks. Outcome 
variables included reproductive hormones, glucose, lipid profiles, insulin 
sensitivity, thyroid, gut microflora and inflammatory status.  
Results: At 12 weeks, non-pregnant women experienced increased levels of 
glucose (86.04 to 87.62mg/dL), insulin (8.72 to 9.37µIU/mL), HOMA-IR (2.1 to 
1.9), p<0.01; and lipid profile: T-Chol (169.5 to 174.9mg/dL), TG (71.0 to 
83.7mg/dL), HDL-C (52.0 to 54.11mg/dL), with p<0.001. For pregnants, glucose 
(86.15 to 82.19mg/dL), HbA1c (5.3 to 5.08%) and TSH (1.71 to 1.36µIU/mL) were 
significantly lower and lipids were higher: TG (73.5 to 126.78mg/dL), T-Chol 
(177.5 to 199.5mg/dL), HDL-C (55.3 to 65.1mg/dL); all p<0.001. Prenatal BMI 
(OR=1.11; p<0.05) was the main predictor of GDM risk. 
Conclusion: IVF therapy worsens lipid profile regardless of IVF outcome. 
Divergent effect of IVF therapy on glucose homeostasis depends on pregnancy 
status, with improved glycaemia in early IVF-conceived pregnancy, and worsened 
in the short term following unsuccessful IVF. The possible longer-term metabolic 
effects of IVF should be a focus for future research. Prenatal BMI appears to be the 
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Infertility is a multifaceted global health concern, and affects 20% of 
couples of reproductive age. In recent decades, there has been a tendency to delay 
childbearing age with contraceptives. Furthermore, the obesity epidemic and 
prolonged exposure to environmental and lifestyle-related stressors are major 
contributors to the increasing incidence of infertility, and the need for its effective 
treatment. The use of assisted reproductive technologies (ART), including 
primarily in vitro fertilisation (IVF), is becoming more prevalent. In the United 
Arab Emirates (UAE), with infertility affecting 50% of women of reproductive age, 
IVF is also very popular because of the accentuated importance of parturition, for 
gender selection and preventing genetically predisposed diseases of first degree 
relative marriages (e.g. thalassemia).      
 Oral contraceptive hormones commonly associate with gastrointestinal side 
effects from changes in gut microflora, in addition to possible adverse effects on 
glucose and lipid metabolism, which in turn may promote insulin resistance and 
inflammation. The concentration of reproductive hormones is much higher when 
used for IVF therapy than for oral contraception. However, confirmation of the 
safety of IVF (both maternal and foetal) remains tenuous. Previous studies have 
focused mainly on risk of obstetric complications in IVF-conceived pregnancies, 
with relatively few studies investigating possible effects of IVF hormones on 
maternal metabolic, endocrine and inflammatory status.    
 Pregnancy is characterised by profound hormonal-driven changes with 
consequences for metabolic, endocrine and inflammatory status and possible 
implications in gut microflora. Dyslipidemia, hyperglycaemia, insulin resistance 
and/or oxidative by-products result in adverse maternal and foetal outcomes in the 
short-term and may predispose to chronic conditions later in life. The “diabetogenic 
state” of pregnancy results from exaggerated adiposity accretion, impairment in 
glucose and insulin homeostasis, and lipolysis. Growing evidence supports the 
notion of intestinal microbiota as an endocrine-metabolic organ, given its 
significant contribution in different physiological regulations. Functional and 
composition distortion in intestinal microbiota contribute to immunity impairment, 





gestational diabetes mellitus (GDM).      
 Given the elevated concentrations of IVF hormones combined with 
gestational hormones, metabolic, endocrine and inflammatory changes may 
manifest earlier in IVF-conceived pregnancies. The relationship of IVF hormones 
to the known diabetogenic and atherogenic effects of pregnancy requires further 
investigation. Reliable predictive factors for possible metabolic, endocrine and 
inflammatory sequelae of IVF therapies are required. Such factors could help 
prevent or at least identify at an early stage women who are at “high risk” for 
maternal and/or foetal complications, such as GDM. The first objective of this study 
was to assess the impact of IVF-related hormones on maternal glucose and insulin 
homeostasis, metabolic profile and inflammatory status. The second objective was 
to explore early predictors for GDM and assess the applicability of existing well-














































In this section, the main causes of infertility will be outlined followed by an 
overview of the common treatment modalities including known maternal and foetal 
risks and complications, with a focus on IVF therapy. Also, a review of the existing 
literature on maternal metabolic, endocrine and inflammatory effects of oral 
contraceptives and IVF therapies in pregnancy will be conducted. Finally, the well-




Infertility is a global health concern, and affects 20% (1 in 5) of couples of 
reproductive age. Infertility is defined as the “inability to conceive after 12 months 
of unprotected intercourse, and 6 months for women 35 years of age or older”1,2. 
Subfertility refers to couples who can still conceive but with more difficulty, an 
example of which is a 40-year-old woman who can get pregnant but her chances 
are lower compared with a younger woman3. In the UAE, women infertility affects 
30 to 60% depending on the age group of women considered4.  
2.1.1. Female Infertility  
 
Many factors are associated with infertility in women. Mechanical 
impairment of the reproductive system accounts for about 35% of female infertility, 
and includes damaged or blocked fallopian tubes, fibroids and endometriosis1,5. 
Age has a significant impact on female fertility, affecting both quality and quantity 
of eggs: reproductive age peaks in the 20s and early 30s and starts to decline after 
the age of 35 years. Consequently, the chances of pregnancy are about 25–30% in 
the early 30s and 10% or lower after 40 years of age6–8. Problems with ovulation 
and hormonal-related disturbances are common causes of infertility in women. 
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in 
women of reproductive age and is associated with obesity, hyperinsulinemia and 
insulin resistance9–12. Although frequently co-existent with PCOS, there is evidence 
to support the notion that overweight and obesity are independent contributors to 





manifesting with anovulation13–15. Furthermore, a lower serum levels of anti-
müllerian hormone (AMH, measurement of ovarian reserve) were reported in obese 
women with PCOS16. Due to the adverse effects of obesity on female fertility 
outlined here, obese women undergoing IVF may require higher doses of 
stimulating hormones. Obesity reduces the success rate of IVF, with a diminished 
endogenous hormonal response and increased risk of adverse pregnancy 
outcome17–19. 
Extensive studies have asserted the importance of preconception weight-
loss in obese women with or without PCOS to improve metabolic parameters, 
reproductive performance and pregnancy outcomes20,21. Multiple esteemed 
societies (including American College of Obstetricians and Gynaecologists, the 
Maternal Fetal Medicine Association and the European Society of Human 
Reproduction and Embryology21–23) uniformly recommend delaying fertility 
treatments, with a greater focus on weight-loss preconception in obese women. The 
British Fertility Society24 recommends women to have a BMI <35 kg/m2 before 
commencing any fertility treatment. The British National Institute for Health and 
Clinical Excellence (NICE)25 recommends a preconception BMI of 19–30 kg/m2. 
 In the UAE, the incidence of PCOS and infertility is a rising concern 
especially with increased obesity prevalence amongst women. In fact, the UAE is 
listed amongst the top 10 countries worldwide for obesity prevalence26,27 and has 
one of the highest rates of PCOS, accounting for 60% of Gulf women and 30% of 
women of Indian origin28. Regarding recommendations for fertility treatments, the 
health authority of Abu Dhabi (HAAD) in UAE sets the BMI upper limit to 38 
kg/m2. The BMI cut-off is less strict in advanced maternal age, since delaying 
fertility treatment for such cases may result in inevitable infertility. Underweight 
women (BMI<18.5) may also experience irregular menstrual cycles and infertility, 
often secondary to insufficient body fat stores with adverse implications for normal 
sex axis functioning29–32. Thyroid dysfunction can also impair menstrual cyclicity 
and fertility33,34.  
Studies have compared different dietary compositions and their effect on 





there is much controversy in this literature, and the optimal “fertility diet” has yet 
to be identified. A healthy and balanced lifestyle improves egg quality7. Heavy 
caffeine consumption (500 mg/day or more than 5 cups/day) and high mercury 
levels from seafood impair fertility39. Smoking hastens depletion of follicle 
reserves8. Validation of the effects of these dietary and environmental factors on 
female fertility requires further research focus.  
2.1.2. Male Infertility Factors  
 
Male factors represent 30% of infertility cases40,41. Assessment of male 
fertility involves evaluation of semen (including volume and concentration), sperm 
(including number, shape [morphology] and motility) and the reproductive tract. 
Oligospermia (low sperm count), teratospermia (abnormal sperm morphology) and 
asthenozoospermia (impaired sperm motility) are the most commonly reported 
causes of male infertility. Azoospermia (complete absence of sperm production) is 
a less common cause of male infertility42,43. In men, fertility is adversely affected 
by advanced age, smoking and obesity, similar to women41,44,45, although age-
related effects are less pronounced in men, with fertility only declining after the age 
of 50 years8. High alcohol and caffeine intake and the use of recreational drugs may 
also contribute to male infertility46,47. Additionally, poor control of medical 
conditions (such as diabetes and cystic fibrosis) can adversely affect sperm quality 
and ejaculation48.  
2.1.3. Other Infertility Factors 
 
A combination of male and female factors account for 20% of infertility 
cases, and the remaining 15% of infertility cases are idiopathic or unexplained 40,41. 
Having outlined the underlying causes of infertility, there follows an outline of 










2.2. Assisted Reproductive Technology 
 
Assisted reproductive technology (ART) describes various procedures that 
help couples to conceive. ART options include natural cycle, time intercourse, 
intrauterine insemination (IUI), gamete intra-fallopian transfer (GIFT), zygote 
intrafallopian transfer (ZIFT), egg donor, and in vitro fertilisation (IVF)41,49 (Table 
1).  
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✓  - - - 
Second choice of 
treatment 
IUI Small dose - ✓   Male factor 




-Failure of other 





Mini IVF Small dose ✓  - ✓  
-At risk of OHSS 
-Minor infertility 
factors 
Natural IVF - ✓  - ✓  
- Poor responders 




-At risk of OHSS41 








2.2.1. In Vitro Fertilisation (IVF)  
 
In vitro fertilisation (IVF) is the most commonly performed ART-based 
technique, given its high success rate. IVF is the treatment of choice for unexplained 
infertility20,49. In addition to the listed factors in Table.1, IVF is very popular in the 
Arab World because of the accentuated importance of parturition regarding gender 
selection, and prevention of genetically predisposed diseases of first relative 
marriages (e.g. thalassemia). The success rate of IVF depends on multiple factors. 
Women’s age is one of the main predictors of IVF outcome. Success of IVF 
declines with age, especially after the age of 35 years1. Obesity also negatively 
affects IVF outcome, with severity of obesity strongly associates with poorer 
outcome. According to Khairy (2017)20, obesity induces molecular changes in 
oocytes, which impairs embryo quality and endometrial receptivity. Furthermore, 
number of transferred embryos may predict IVF success: with more embryos 
transferred there is a higher chance of pregnancy. The number of transferred 
embryos depends on the women’s age41. 
2.2.2. Obstetric Risks and Complications of IVF Therapy  
2.2.2.1. Risks of IVF Therapy on Maternal Outcomes  
 
Despite a steady increase in the medical treatment of infertility with ART, 
there is still a lack of published evidence on its safety. Compared with other ART 
treatments, IVF associates with increased maternal risks and complications, since 
there is alteration of the normal physiological development of pregnancy during 
IVF. Furthermore, use of stimulating agents can also adversely affect pregnancy 
outcome, including association with ovarian cysts, ovarian enlargement and 
Ovarian Hyper Stimulation Syndrome (OHSS)41. In extreme cases (3–5%), a 
serious complication of ovarian stimulation, OHSS may ensue. OHSS is an 
exaggerated ovarian response, with a significant increase in oestrogen level and 
enlarged ovaries, resulting in shift in fluid to extravascular spaces (mainly 
abdominal), and in severe cases around the lungs50.  
 Ectopic pregnancy is considered as a complication of pregnancy and is 





is related to increased volume of fluid injected with the embryo, or the location of 
the embryo transfer being close to the fallopian tubes. Pregnancy loss after 12 
weeks is also more common in IVF-conceived pregnancies51,52. Furthermore, 
multiple pregnancies account for 25% of IVF-conceived pregnancies, given that 
more than one embryo can be transferred to increase chances of pregnancy49. 
However, although twin and triplet pregnancies have a higher complication rate 
overall compared with singleton ones (including preeclampsia, GDM, 
thromboembolism and pre-term delivery)41,53,54, complication rates overall are 
similar between IVF-conceived and spontaneously-conceived pregnancies55,56.  
Future studies should focus on obstetric outcomes with IVF-conceived 
pregnancies in larger cohorts, well matched with spontaneous pregnancies, 
including those that result in multiple pregnancies. One reason for the frequent 
categorization of women undergoing IVF therapy as ‘high risk’ may relate to higher 
rates of maternal adverse outcomes with IVF-conceived pregnancies, as they 
usually present with advanced age, high BMI (>30 kg/m2) or a pre-existing medical 
condition such as PCOS or impaired thyroid function57,58. A higher prevalence of 
spontaneous abortion occurs in IVF-conceived pregnancies in women who are 
obese and/or have a history of PCOS10.    
IVF-conceived pregnancy is a ‘high-risk’ intervention with increased risk 
for maternal and obstetric complications. These include miscarriage, vaginal 
bleeding, frequent hospitalisation, gestational hypertension, GDM and preterm 
labour6,52,59–62. However, there is some controversy in the literature regarding the 
actual risk of adverse obstetric and maternal outcomes in IVF-conceived 
pregnancies: in a large retrospective study by Kozinszky et al.55, data did not show 
increased rates of obstetric complications with IVF pregnancies. Caesarean section 
is also more common with IVF pregnancy63. Women may consider IVF-conceived 
pregnancy as “precious” after many years of infertility, and choose caesarean 
section to prevent perceived complications from a natural vaginal delivery, and not 
necessarily because of medical necessity64.  
IVF hormonal therapy may also associate with increased risk of breast and 





more studies are needed65–67.  
2.2.2.2. Risks of IVF Therapy on Foetal Outcomes  
 
Risk of congenital malformation was shown to associate with IVF, 
especially with multiple pregnancies62,66,68,69. However, when controlling for age 
and parity, this association is not always significant70. Mixed reports exist regarding 
foetal outcomes of IVF-conceived pregnancies. Whilst some studies suggest that 
IVF may predispose to intrauterine growth retardation, foetal anomalies, birth 
defect, and perinatal mortality56,71,72, others show no difference in foetal outcomes 
between spontaneous and IVF-conceived pregnancies59,69,73. In one study, it was 
shown that IVF-conceived children are predisposed to obesity, insulin resistance, 
type 2 diabetes mellitus (T2DM) and cardiovascular disease in adulthood74. Further 
prospective studies are required to clarify the nature and extent of adverse effects 
of IVF on offspring, regarding both foetal development and longer-term effects that 
may manifest in adulthood.  
 
2.3. IVF Therapy, Metabo-Endocrine, Inflammatory and Gut 
Profiles 
2.3.1. Endocrine Function in IVF-conceived Pregnancy  
 
Key hormones control the female reproductive system: luteinizing hormone 
(LH), follicle-stimulating hormones (FSH), oestrogen, progesterone and beta-
human chorionic gonadotrophin (β-HCG). A rise in serum LH triggers ovulation. 
The rise in LH also stimulates the ovaries to secrete progesterone. Whilst oestrogen 
and progesterone have multiple metabolic and endocrine effects throughout the 
body, there is confinement of the effects of FSH and LH to the ovary. Under normal 
physiological control, oestrogen and progesterone (also called ‘gestational’ or 
‘maternal’ hormones) rise linearly during pregnancy, and play crucial roles in 
supporting pregnancy and normal foetal development75–77. Progesterone, produced 
primarily from the ovaries, acts on the uterus to prepare its lining for embryo 
implantation. During pregnancy, progesterone is also produced by the placenta1. 





progesterone dominate the first and second halves of gestation respectively. β-HCG 
hormone is one of the early indicators of pregnancy. Addressing the well-known 
physiological effects of reproductive hormones from use of oral contraceptives and 
pregnancy should enable prediction of the potential adverse maternal impact of IVF 
therapy.  
2.3.2. Metabolic Profile in IVF-conceived Pregnancy 
2.3.2.1. Glucose and Insulin Homeostasis in Pregnancy  
 
During early pregnancy, fasting plasma glucose level is similar to that of 
non-pregnant women, and usually remains constant throughout pregnancy. Glucose 
tolerance is also commonly within normal range or slightly enhanced in early 
pregnancy78. Insulin, the principal modular of glucose homeostasis, often only rises 
significantly in the serum after the second trimester. Insulin sensitivity is 
unchanged or even increases in early gestation, to ensure sufficient glucose supply 
to the foetus79–81. During the second and third trimesters, insulin sensitivity 
frequently diminishes to 50–70% of first trimester levels (measured by 
hyperinsulinemic-euglycaemic glucose clamp technique). In addition, insulin 
requirement increases after 26th week of gestation, to possibly 50% more compared 
to pre-pregnancy levels82–86. Insulin resistance, reflected by increased homeostatic 
model assessment of insulin resistance (HOMA-IR), drives increases in serum 
insulin level. The presence of normoglycaemia in pregnancy despite prevailing 
insulin resistance may reflect a physiological adaptation of metabolism regarding 
lipid and carbohydrate regulation87–89. The state of insulin resistance favours 
glucose availability to the foetus, maternal fat accretion and use of lipids (free fatty 
acids) as source of energy by the mother88. Reduced insulin sensitivity in pregnancy 
can sometimes reach comparable levels to that in T2DM88,90.   
Gestational hormones play important roles in insulin homeostasis. Whilst 
oestrogen enhances insulin release and binding to its receptor, progesterone 
actually reduces insulin binding to its receptor and hence impairs glucose transport. 
Therefore, a possible explanation for the diabetogenic effect of pregnancy relates 





second and third trimesters, that manifests in reduced insulin sensitivity, 
hyperinsulinemia, and impairment of ‘pre-implantation environmental state’10. 
Other placental hormones contribute to the diabetogenic effect of pregnancy, which 
include: human placental lactogen (HPL), human chorionic gonadotrophin (hCG), 
corticotrophin‐releasing hormone (placental CRH), relaxin, kisspeptin and growth 
hormones. Concentrations of these hormones augment exponentially from the 
second trimester. Placental CRH triggers production of maternal 
adrenocorticotrophin hormone, and in turn provokes cortisol secretion typically 
from mid-gestation91. Placental hormones, referred as diabetogenic hormones, 
induce anti-insulin action and trigger lipolysis92. Consequently, there is a reduction 
in peripheral and hepatic insulin sensitivity, sparing of carbohydrates (glucose) for 
the foetus and decreased maternal use of glucose as energy. As a result, insulin-
stimulated glucose uptake is reduced at the muscle and liver levels and hence 
promote glycogenolysis (breakdown of stored glycogen into glucose)78,88,92.  
The diabetogenic effect of pregnancy stems hence from impairment of 
insulin sensitivity, and increased beta-cell activity in response to a greater 
requirement for insulin86,93–95. Although insulin resistance plays an important role 
in the aetiology of numerous adverse outcomes during pregnancy (such as GDM, 
preeclampsia and miscarriage), the mechanisms implicated remain incompletely 
understood81,96,97.  
2.3.2.2. Glucose and Insulin Homeostasis and IVF Therapy  
  
Interestingly in mice models, IVF associates with glucose intolerance98. In 
humans, studies on oral contraceptive therapies (oestrogen and progesterone 
combination) report comparable findings in relation to their impact on glucose 
metabolism and insulin homeostasis. Impairment of insulin sensitivity and glucose 
tolerance were commonly shown with the use of oral contraceptives, as evidenced 
by higher glucose and insulin levels99–101. Whilst some research findings suggest 
that insulin resistance is induced by progesterone, others suggest that this is likely 
oestrogen-related, and that progesterone only affects insulin half-life99,102,103. 





glucose and insulin, whereas 1.25 mg/day was associated with a 25% decrease in 
insulin sensitivity. Given that the dose of gestational hormones administered during 
IVF therapy is higher than that used for combined oral hormonal contraception, it 
is not possible to extrapolate glycaemic and metabolic effects of combined oral 
hormonal therapies to those used for IVF.      
 Compared to spontaneously-conceived pregnancies, women with IVF-
pregnancies are more likely to develop GDM. This association remains following 
adjustment for maternal and gestational age, and parity104,105. Higher prevalence of 
GDM in IVF-conceived pregnancy likely results from the large dose of exogenous 
hormones (oestrogen and progesterone) administered during the treatment and 
which in turn alter the normal physiological development of pregnancy (levels of 
reproductive hormones are adjusted with medications for optimal control of IVF 
cycle). It is also possible that the increased risk for GDM in IVF-conceived 
pregnancies may stem from association with prenatal obesity or maternal PCOS 
(conditions that are not always specified)106,107. Alternatively, association of IVF 
with GDM may develop indirectly from the effects of IVF therapy on body fat 
accumulation, or directly from the procedure itself, through incompletely 
understood mechanisms. Multiple pregnancies, more common in IVF-pregnancy 
compared to spontaneously-conceived pregnancy, also constitute a powerful risk 
factor for GDM108. However, human data are severely limited in relation to the 
effects of IVF on insulin and glucose homeostasis during early pregnancy. Further 
studies are required to explore the potential for IVF-related hormonal therapy to 
hasten (physiological changes to occur in early pregnancy instead) or augment the 
diabetogenic effect of pregnancy. Such data will likely provide further insight into 
early predictors of GDM. 
2.3.3. Cardiovascular and Inflammatory Risks in IVF-conceived Pregnancy  
2.3.3.1. Inflammatory Markers with IVF Therapy  
 
Pregnancy-related inflammatory response is induced by physiological and 
hormonal changes, and detectable as early as embryo implantation109. Gestational 





as C-reactive protein, CRP)110. A list of inflammatory and gut-related parameters 
to assess pathophysiological changes of pregnancy is presented in Table 2.  
C-reactive protein (CRP), one of the commonly measured inflammatory 
markers, appears to increase with the use of oral contraceptives, mainly in women 
<35 years111,112. Based on this observation, IVF-related therapy may also stimulate 
an inflammatory response. Serum levels of high-sensitivity CRP (hs-CRP) also 
correlate with age and BMI, factors that both associate with infertility and often 
occur in those seeking IVF therapy. Furthermore, obesity associates with 
inflammation and is itself often an independent cardiovascular risk factor in obese 
women who use oral contraceptive therapies113,114. There is controversy regarding 
the predictive utility of CRP for conception failure post-IVF109. 
Adiponectin, a useful marker of inflammation and insulin sensitivity, has 
not been comprehensively studied in women who undergo IVF115. Furthermore, 
serum adiponectin levels gradually decline during pregnancy, secondary to 
hormonal fluctuation113,116. 
 
Table 2: Inflammatory and Gut Microflora Parameters  
 
Biomarkers Description Specification/Use 
Interleukin (IL-6), 
tumour necrosis factor 
(TNF-α), TNFsR1 
Pro-inflammatory markers 
as a result of increased 
levels of endotoxins or 
stress117,118. 
Levels increased in second 
trimester of pregnancy and 
may predict insulin 
resistance119. 
 
- IL-6 is over-expressed in 
obesity and 
inflammation119. 
- More studies are needed 
to assess TNF-α potential 
role as GDM predictor 
independently of BMI119. 
- Indirect effect on insulin 
resistance and gut-related 
changes. 
Adiponectin 




glycaemic and insulin 
sensitizing properties120. 
Low levels in early 
pregnancy predicts 
increased risk of GDM113. 
- Involved directly in 
glucose and lipids 
metabolisms with receptors 
in the liver, muscle and  
adipose tissue (AdipoR1 
and AdipoR2)121. 
- Low level in PCOS113, 
and should be more 
elaborated. 
Leptin 
Type of adipokines, 
adipocyte or placental-
Involved indirectly in 





derived hormone with pro-
inflammatory 
properties120. 
Contribute to regulation of 
gonadotrophin releasing 
hormones secretion116. 
Hyperleptinemia in early 
pregnancy predicts a 
higher risk of GDM122. 





Type of adipokines, 
adipocyte‐derived 
hormone, which triggers 
secretion inflammatory 
cytokines and hence 
contributes to insulin 
resistance120. 
 
Insulin-like action, but 
more prospective studies 
should be conducted in 
regard to its role in glucose 
homeostasis116. 
Pentraxin, such as 
pentraxin 3 and CRP 
In early pregnancy, low 
level is associated with 
subsequent development 
of GDM124.  
 
Pentraxin 3 has anti-
microbial and anti-
inflammatory properties 
but is produced at site of 
inflammation124. 
Lipopolysaccharide 
binding protein (LBP) 
 
Soluble acute-phase 
protein, produced by 
hepatocytes and intestinal 
epithelial cells. 
Binds to LPS and 
provokes immune 
response by triggering 
cluster of differentiation 
14 (CD14) inflammatory 
signal cascade125,126.  
- Surrogate marker of 
endotoxemia127,128 and a 
better marker of microbial 
translocation (abnormal 
passage of bacteria of the 
intestinal lumen through 
the epithelial mucosa 
barrier and possibly 
reaching external tissues) 
compared to LPS125. 
- Stable in blood and half-




negative cell walls in gut 
lumen. 
- High variability 
throughout the day125. 
- Half-life is about 2 hours, 
and hence evaluation of 
endotoxins by LPS may 
not be reflective enough126.  
- Analysis technique is 
more complex than LBP 
and more costly.  
- Assay is more sensitive to 
effect of detergents, urea, 
and pH125. 
rRNA 
Placental or faecal test for 
microbiome test with 16s 
RNA ribosomal 
sequencing129,130.  
Cumbersome at a clinic 











protein and bile acids into 
SCFA (butyrate, acetate 
and propionate)131. 
Beneficial for host and 
used as source of energy 
for epithelial cells and 
maintaining gut 
homeostasis118. 
Abnormal level of SCFA 
triggers inflammatory 
response132. 
- Measured in blood 
(serum or plasma) or stool. 
- Hepatic and/or other 
tissues absorption and 
rapid uptake, measurement 
of SCFA in stool and blood 
engenders little 
information131.  
- Low concentration in 
blood133. 
 
Branched chain amino 
acids 
Microbial synthesis: 
isoleucine, valine, leucine, 
tyrosine and 
phenylalanine. 
Contribute to glucose 
homeostasis131; and levels 
associate with increased 
diabetes risk115. 
- Tracer needed for 
analysis. 
- Invasive, time consuming 
and not practical for 
pregnant women131. 
Soluble CD14 (sCD14) 
Secreted by the liver and 
intestinal monocytes in 
response to LPS and other 
bacterial substances125 
Useful biomarker for 
clinical endotoxemia118. 
 
2.3.3.2. Lipid Metabolism in Pregnancy 
 
In addition to an inflammatory response, pregnancy also induces changes in 
lipid and lipoprotein metabolism, usually evident following the first trimester. Early 
pregnancy dyslipidemia (hypercholesterolemia and principally 
hypertriglyceridemia) associates with increased risk of adverse outcomes both for 
the mother (including preterm delivery, preeclampsia and GDM) and for the foetus 
(including macrosomia and large-for-gestational-age)134–136. Consequently, 
screening for lipid disorders prior to pregnancy and its appropriate management is 
important.           
 Lipid-lowering agents (e.g. statins) are possible teratogens and hence not 
recommended during pregnancy. However, available evidence to support such 





parameters during pregnancy135,138, others show only significant increases in 
triglycerides (TG) and very-low-density lipoprotein (VLDL), and a decrease in 
low-density lipoprotein cholesterol (LDL-C)134,135,138,139. Hypertriglyceridemia 
results from pregnancy-related increased body fat and lipolytic activity, required to 
support pregnancy and in preparation for breastfeeding134,139. Impairment in insulin 
sensitivity during pregnancy may also impair lipid metabolism, through reduced 
ability of insulin to suppress lipolysis116. Insulin resistance and hyperinsulinemia 
also occur commonly in obesity and PCOS, and associate with preconception 
hyperlipidemia140. Given the high prevalence of obesity and/or PCOS in women 
undergoing IVF, screening and management of dyslipidemia preconception is 
important to reduce the likelihood of development of pregnancy-related 
complications. 
2.3.3.3. Lipid Metabolism and IVF Therapy  
 
Studies on the effects of oral contraceptive therapies on lipid profile report 
conflicting data in relation to changes in LDL-C and high-density lipoprotein 
cholesterol (HDL-C) levels, but strong evidence regarding increases in TG 
level101,141–143. Elevated serum levels of oestrogen triggers hepatic synthesis of 
lipids, with increased serum levels of TG, total cholesterol (T-Chol) and HDL-
C138,144,145. In line with this, hypertriglyceridemia is thought to be oestrogen-dose-
related86,142. Hypertriglyceridemia subsequently impairs insulin sensitivity101. 
According to Godsland et al.143, oral contraceptives predispose to a higher risk for 
coronary heart disease, mediated through increased TG, LDL-C and insulin levels, 
and decreased HDL-C. The literature is deficient regarding data on the effects of 
IVF hormonal therapies on lipid profile, and potential effects of the latter on 
augmentation of the atherogenic nature of pregnancy. 
2.3.4. Gut Microflora in IVF-conceived Pregnancy 
2.3.4.1. Gut Microflora in Pregnancy 
 
The gut microbiota can trigger an inflammatory response through mediation 





binding protein (LBP), an acute-phase protein. LBP binds bacterial compounds, 
including lipopolysaccharides (LPS). LPS is an outer membrane component of 
gram-negative bacteria that normally reside within the gut and form the microbiota. 
Under normal condition, LPS (also called endotoxins) remains in the gut, but when 
it crosses over a leaky gut wall into the circulation it becomes problematic. Gut wall 
permeability (with leakage of LPS into the bloodstream) is likely influenced by 
stress, a high fat/energy-dense diet, or the use of certain hormonal therapies. In the 
presence of endotoxins in the circulation, LBP is rapidly synthesized by the liver, 
and released into the circulation to bind LPS. The binding of LBP with LPS 
provokes an immune response and triggers cluster of differentiation 14 (CD14) 
inflammatory signal cascade125,126. This results in a condition called ‘metabolic 
endotoxemia’117,147–149. LBP is thought to be a surrogate marker of endotoxemia, 
given that it is considered as a more stable biomarker than LPS126. More research 
is needed to elucidate whether LBP can act as a strong surrogate marker of LPS and 
its related impact on inflammation and gut flora. LBP have also been associated 
with metabolic diseases, such as obesity, diabetes, and non-alcoholic fatty liver 
disease127; further research is required to assess its possibility in predicting 
metabolic impairments of pregnancy, including insulin resistance and early 
GDM150. 
Maternal gut microbiota undergoes microbial adaptation with restriction of 
species count and floral diversity from early to late pregnancy, which may 
predispose to gestational micro-inflammation and metabolic impairments151 (Refer 
to table 2 for a list of markers). Pregnancy-related changes in the gut microbiota 
may mediate metabolic dysfunction including reduced insulin sensitivity152. 
Accordingly, reduced maternal microfloral diversity was reported in the first 
trimester in those who later developed GDM132. In fact, maternal gut floral 
dysbiosis (imbalance of gut microbiota) associates with various pregnancy-related 
complications, such as insulin resistance, preeclampsia, miscarriage, intrauterine 
growth retardation and preterm delivery. Furthermore, maternal dysbiosis of the 





2.3.4.2. Gut Microflora and IVF Therapy 
 
Female sex hormones influence profoundly microbiota composition within 
the mouth, vagina and gut. There is a likely role for oral contraceptives in the 
development of inflammatory bowel disease (Crohn’s disease and ulcerative 
colitis)155. Furthermore, gastrointestinal side effects commonly occur with oral 
contraceptive therapies. Oral oestrogen and progesterone treatment has been shown 
to affect gut permeability, LPS signalling and cytokine-mediated inflammatory 
diseases156,157. Dysbiosis is possibly related to insufficient or overloaded oestrogen 
and engenders an inflammatory response, resulting in metabolic and 
immunological disorders (e.g. T2DM)149. It is speculated that changes in gut 
microflora, serum LBP and LPS levels may also occur with IVF-related therapies, 
given the higher dose of reproductive hormones used compared with oral 
contraceptives and the stress of the procedure. Mediation of the inflammatory 
effects of IVF therapies may occur through changes in the gut microbiota and serum 
levels of LBP and LPS. Such inflammatory effects may extend throughout the IVF-
conceived pregnancy. There are currently no reported studies on the effects of IVF 
treatments and IVF-related pregnancies on lipopolysaccharides markers (such as 
LBP and LPS) and gut microbiota. Assessment of gut permeability during 
pregnancy (through IVF- and spontaneous conception) would form a novel focus 
for future research.  
2.3.5. Endocrine Function in IVF-conceived Pregnancy 
2.3.5.1. Thyroid Function in Pregnancy 
 
Thyroid dysfunction impairs menstrual cyclicity, female fertility and 
pregnancy outcome, and is classified as the second most common endocrine 
disorder in women of reproductive age33,158. Hypo- and hyperthyroidism are the 
two main types of thyroid disorder that adversely affect sex-hormone-binding and 
accordingly their own serum levels. Thyroid dysfunction affects both the duration 
and flow of menstrual cycle. Disorders in length of cycle include: oligomenorrhea 
(light or infrequent menstruation, ≥35 days), polymenorrhea (cycles with intervals 





and disorders of menstrual flow are: hypomenorrhea (decreased flow), 
hypermenorrhea (increased flow) and menorrhagia (heavy and prolonged menstrual 
period)159. In women of reproductive age, oligomenorrhea and amenorrhea are the 
most common abnormalities associated with hyperthyroidism, followed by 
hypomenorrhea, and anovulation160,161. Plasma oestrogen and LH levels were found 
to be higher in women with hyperthyroidism compared to their controls during all 
phases of the menstrual cycle162. Hypothyroidism is associated with 
polymenorrhea, menorrhagia and hypermenorrhea161–163. 
In early stages of pregnancy, the foetal thyroid gland is not yet fully 
developed and hence maternal thyroxine plays a vital role for the foetus. After 10 
weeks, both maternal and foetal thyroid hormones are necessary to satisfy the 
increased needs of gestation and adequate foetal neurological development158,164. 
Oestrogen has a significant impact on thyroid-stimulating hormone (TSH) secretion 
and thyroid gland activity165. TSH is in charge of triggering thyroid hormones 
secretion (T3: triiodothyronine and T4: thyroxine). During pregnancy, “oestrogen 
dominance” interferes with thyroid metabolism by stimulating hepatic thyroxine-
binding globulin secretion, thereby reducing levels of free thyroid hormones (T3 
and T4)166–168. In addition, serum TSH level is suppressed throughout pregnancy, 
with typically a low-normal level in the first trimester169,170. There is also an 
increase in serum β-HCG (pregnancy indicator hormone) during pregnancy, the 
effect being particularly pronounced in twin pregnancies171. β-HCG has stimulatory 
effects on the TSH receptor and may drive over-production of thyroid hormones 
during pregnancy, and also contributes to suppression of TSH production33,172.  
Recurrent pregnancy loss, preterm birth and placenta abruption associate 
with high TSH level40,96,172. Consequently, it is not uncommon for pregnant women 
to be prescribed with thyroid medications on their first trimester, as soon as thyroid 
impairment is detected58,164. In addition, previous studies reported that pregnant 
women with hypothyroidism (TSH level elevated, T4 and T3 levels normal or 
low164) often require increased doses of thyroxine by about 30–45%169,173,174. Both 
hypo- and hyperthyroidism impair insulin sensitivity, and this may ultimately affect 





active form T3175,176.  
2.3.5.2. Thyroid Function and IVF Therapy 
 
Oral contraceptives and pregnancy alter thyroid function in similar ways, 
likely an oestrogenic effect. However, although the mechanisms are similar, more 
pronounced changes in thyroid hormones likely occur during gestation. The 
difference in magnitude of thyroid effects between pregnancy and oral 
contraceptive therapies likely relates to exogenous oestrogen therapy having a 
dose-dependent effect on increasing serum thyroxine-binding globulin and total 
serum thyroxine levels in those with normal thyroid function93,145,173. In contrast, 
few studies have determined changes in thyroid hormone level to be progesterone-
related177.         
 Regarding IVF therapies, in addition to the exogenous oestrogen, GnRH is 
also administered, the latter having been reported to affect levels of thyroid 
hormones (likely through indirect stimulation of gonadotrophin release and 
increased production of oestrogen)178. GnRH hormone (from the hypothalamus) 
stimulates FSH and LH synthesis that in turn influence serum levels of oestrogen.  
Impaired thyroid function predicts poor IVF fertilisation outcome, hinting 
a role for thyroxine in oocyte physiology, and more importantly emphasising the 
importance of treating abnormal thyroid levels preconception179. The acceptance 
and validity of TSH range of 0.4–4.0 µIU/mL is still debatable with IVF therapy180 
and the American Thyroid Association recommends a cut-off of <2.5 
µIU/mL170,181,182. Preconception TSH level exceeding 2.5 µIU/mL was correlated 
with a lower gestational age (38.5 vs 38.0 weeks for singletons and 36.0 vs 34.6 
weeks for twin pregnancy) and lower birth weight (7.33 vs 6.78 lbs for singletons 
and 5.36 vs 4.83 lbs for twin pregnancy) according to Baker et al.183. In contrast, 
Kilic et al.184 stated that neither the embryo grades nor the number of fertilised eggs 
differ among women undergoing IVF, but the pregnancy ratio was lower if 
presenting with impaired thyroid level and/or positive anti-thyroid antibodies. 
There is a lack of data in the current literature on thyroid status in IVF-conceived 





effects of oestrogen-related thyroid dysfunction during IVF-conceived pregnancy, 
this should be a focus for future research.  
 
2.4. Early Predictors of Gestational Diabetes Mellitus 
2.4.1. Anthropometrics and Medical History  
 
Gestational diabetes mellitus (GDM) is a growing concern worldwide and 
a threat for maternal and foetal health during pregnancy, childbirth and possibly 
later in life for offspring119,132. Given the high dose of diabetogenic-related 
hormones of IVF therapy, it may be expected that GDM has a higher prevalence in 
IVF-conceived pregnancies. It is therefore important to identify early predictors 
and biomarkers for future onset of GDM in IVF-conceived pregnancies.   
 GDM is defined as “glucose intolerance resulting in hyperglycaemia, with 
onset or first recognition during pregnancy”. GDM has a prevalence of 5–30% 
depending on population characteristics and diagnostic criteria132,185. In the UAE, 
one in every three pregnant women develops GDM186–188. Obesity (body mass 
index, BMI>30 kg/m2), advanced maternal (>35 years) and gestational age, and 
previous GDM are important contributors to the rising incidence of GDM180. Other 
risk factors of GDM suggested by NICE and the American Diabetes Association 
(ADA) include previous baby weight >4.5 kg (or the equivalent to 9.9 lbs), a first-
degree relative with diabetes mellitus, abnormal weight gain during pregnancy and 
certain ethnicities (Hispanic, African-Americans, Native American, South or 
South-East Asian, Pacific Islander or Indigenous Australian South, East Asia and 
Middle East)55,88,189–192. In addition, evidence-based studies report that women with 
PCOS have a significantly higher risk of developing GDM compared to non-PCOS 
controls, independently of obesity. The risk of GDM is particularly high when both 
PCOS and obesity coexist106,193. Current guidelines recommend selective screening 
during pregnancy depending on the presence of high-risk factors, but early general 
screening remains controversial194. The International Association of Diabetes and 
Pregnancy Study Groups recommends all pregnant women to be screened for GDM 





(OGTT). The OGTT is also accepted by the American Diabetes Association for this 
purpose195,196. The 2-hour OGTT glucose cut offs for GDM suggested by the 
International Association of Diabetes and Pregnancy Study Groups are ≤92 mg/dL 
(5.1 mmol/L) for fasting, ≤180 mg/dL (10 mmol/L) for 1-hour and ≤153 mg/dL 
(8.5 mmol/L) for 2-hours197. The World Health Organization (WHO) and the 
American Diabetes Association guidelines 2-hour OGTT criteria for diagnosing 
GDM are a fasting glucose ≥126 mg/dL (≥7.0 mmol/L), 2h ≥ 140 mg/dL (≥7.8 
mmol/L) and/or HbA1c ≥6.5% (≥48 mmol/mol). Pre-diabetes is diagnosed by a 
fasting glucose of 100–125 mg/dL (5.6–6.9 mmol/L) and/or HbA1c of 5.7–6.4% 
(39–47 mmol/mol)195,198,199.  
 GDM has an adverse impact on both mother and foetus. Maternal 
complications include preeclampsia and caesarean delivery. Foetal outcomes 
include macrosomia, large-for-gestational-age, hyperinsulinemia, hypoglycaemia, 
and future risk of obesity and T2DM119,195,198. The literature provides evidence to 
support early detection and management of GDM to prevent maternal and foetal 
complications and improve pregnancy outcome. It is important therefore to identify 
those women at high risk of developing GDM early in pregnancy. Studies have 
explored possible biomarkers for GDM for use as early predictors. These include 
elevated level of glucose, insulin, HbA1c, adiponectin, CRP, TG, HDL-C, vitamin 
D and B 12, LBP and short chain fatty acid196,200,201. 
2.4.2. Glucose Homeostasis Markers   
 
Numerous glucose-related markers were tested and being used as screening 
tools and early markers of potential GDM. Plasma glucose is the first biomarkers 
to monitor during gestation, and which level usually remains within a normal range 
throughout pregnancy. During early pregnancy, dysglycaemia (abnormal glucose 
level) and HbA1c (5.7–6.4% or the equivalent to 39–47 mmol/mol) associate with 
increased risk of future development of GDM later in pregnancy202–204. HbA1c has 
a high sensitivity but low specificity, and therefore unlikely to be a useful screening 
tool in a multi-ethnic population, as in the UAE population205,206. To maintain 





increased to counteract the associated reduction in insulin sensitivity207. 
Consequently, elevated levels of serum insulin during early pregnancy (measured 
<16 weeks of gestation) may also predict increased risk of future GDM 
development208,209. A list of well-documented methods and formulas to measure 
glucose and insulin homeostasis, and evaluating glucose tolerance and insulin 
resistance, is presented in Table 3. 
 
Table 3: Methods to Assess Glucose Homeostasis and Insulin resistance  
 
Methods Description Specification/Use 
Hyperinsulinemic 
euglycaemic clamp 
Known as “gold standard” 
protocol210,211; consists of 
a continuous intravenous 
insulin infusion and 
variable infusion rates of 
glucose212. 
- Costly, time consuming, 
not practical and invasive. 
- Mainly used in research. 
- Clinical application to 
pregnancy is limited213. 
Frequently sampled 
intravenous glucose 
tolerance test  
Computer-assisted model 
also referred a ‘minimal 
model’ which generates an 
insulin sensitivity index 
and a measure of the acute 
endogenous response of 
insulin to glucose212,214. 
- Particularly efficient in 
non-diabetic. 
- Costly, invasive, time 
consuming and not 
practical.  
- Mainly used in research. 
- Clinical application to 
pregnancy is limited213. 
Insulin sensitivity index 
 
Calculated using fasting 
and 120 min post OGTT 
insulin and glucose 
levels215.  
  
- Sensitive but pregnant 
women may refuse doing 
an OGTT early in 
pregnancy if not clinically 
indicated. 
Insulin suppression test 
 
Intravenous infusion of 
glucose and insulin with 
somatostatin or 
epinephrine (to suppress 
endogenous secretion of 
insulin and glucagon)212,214 
- Not practical, invasive 
and complex. 
- Mainly used in research. 
- Clinical application to 
pregnancy is limited213. 
Insulin tolerance test 
Four bolus of insulin are 
provided and blood test is 
collected throughout, and 
plasma glucose decrease is 
measured214.  
- Risk of hypoglycaemia, 
invasive and not practical. 
75g Oral glucose 
tolerance test (OGTT) 
Plasma fasting, 1h and 2h 
glucose levels are 
measured following 75 g 
standard oral glucose 
solution195,196.  
- Conducted around 24-28 
weeks for GDM or earlier 
if risk factors present. 
- Provide information 
about glucose tolerance but 






Ratio of fasting insulin to 
fasting glucose 
Practical, safe, not costly 
and easy. 
Homeostatic model 
assessment of insulin 
resistance (HOMA-IR) 
Quantify insulin resistance 
and beta-cell function.  
Described glucose-insulin 
homeostasis, and is 
calculated as follow: 
fasting glucose (mg/dL) x 







- High sensitivity and 
specificity for assessing 
insulin resistance218. 
- Estimates of insulin 
resistance and deficient 
beta-cell function by 
HOMA-IR correlates 




- Similar results to insulin 
sensitivity index219. 
- More reliable than 
QUICKI method218. 
- Practical, safe, not costly 
and easy to use. 
- Non-invasive and a 
clinically convenient to 
assess pancreatic beta-cell 




sensitivity check index 
(QUICKI) 
Quantify insulin resistance 
and β-cell function; and 
calculated as follows: 1/ 
[log insulin + log 
glucose])214,218 or 1/Log 
HOMA 
Practical, safe, not costly 
and easy to use. 
Matsuda index 
From the OGTT, estimates 
of hepatic and muscle 
insulin sensitivity as 
follows: (10,000/square 
root of [fasting glucose x 
fasting insulin] x [mean 
glucose x mean insulin 
during OGTT])214,220 
Time consuming and 
pregnant women may 
refuse doing an OGTT 
early in pregnancy if not 
clinically indicated. 
 
2.4.3. Other Endocrine and Metabolic Markers  
 
Thyroid hormones influence glucose metabolism through multiple 
mechanisms that include reduction of insulin half-life, promotion of hepatic 
glucose output and glycogenolysis221. In early pregnancy, serum level of thyroid 





women. Given that both hypothyroidism and subclinical hypothyroidism (mild 
form of hypothyroidism with only high TSH level but normal T4 and T3158,170) 
correlate with insulin resistance, early gestation hypothyroidism may be a potential 
risk factor for the development of GDM221. The association between subclinical 
hypothyroidism and increased risk of developing GDM remains controversial and 
warrants further investigation222. 
In relation to pregnancy-associated dyslipidemia and risk of GDM, 
abnormal TG level predisposes to increased risk of GDM compared to those with a 
normal TG level. Elevated levels of TG (>137 mg/dL or the equivalent to 1.55 
mmol/L) was associated with higher GDM risk even after adjusting for pre-
pregnancy adiposity223. Possible association of GDM with other lipid markers (T-
Chol, LDL-C and HDL-C) is less clear223–225. A study by Abell et al. reported that 
HDL-C ≥85.5 mg/dL during the first trimester of pregnancy reduced GDM risk119.  
The logarithm of TG/HDL-C ratio is commonly used as an atherogenic marker, and 
elevated ratio level (Log TG/HDL-C >0.099) may identify pregnant women with 
higher risk of GDM before 24 weeks of gestation226.    
2.4.4. Adiponectin  
 
Recent studies explore adipokines (such as adiponectin and leptin) as an 
early predictor of GDM. Adipokines are produced by adipose tissues and serve as 
a network that communicates different organs and physiological processes, such as 
glucose and lipid metabolisms, energy balance, insulin sensitivity, immunity and 
inflammation116.  
Adiponectin plays a key role in glucose homeostasis regulation through 
anti-glycaemic and insulin sensitizing effects. Adiponectin decreases hepatic 
glucose production and increases insulin action and peripheral glucose uptake. Low 
serum level of adiponectin associates with T2DM, insulin resistance, obesity, 
PCOS and preeclampsia. Serum adiponectin inversely associates with BMI, fasting 
glucose and insulin, and TG levels, and positively associates with HDL-C levels116. 
Maternal adiponectin secretion gradually declines during pregnancy, secondary to 





changes are more pronounced with advancing gestational age113. Furthermore, 
adiponectin has anti-inflammatory effects116. Low levels of serum adiponectin in 
the later stages of pregnancy may contribute towards the development of 
pregnancy-related inflammation, with release of pro-inflammatory cytokines 
(TNFα ad IL-6). This in turn may further exacerbate insulin resistance116.  
A lower serum level of adiponectin occurred early in pregnancy in 
overweight and obese women who later developed GDM compared to their non-
GDM controls. This association of serum adiponectin with GDM was still present 
after adjusting for differences in pre-pregnancy BMI and insulin sensitivity 
between the two groups116,119,120. Level of adiponectin ≤6.4 μg/mL was associated 
with higher risk of developing GDM later in gestation113,227. GDM is characterised 
by inflammation and insulin resistance, interconnected with adiposity. 
Inflammation aggravates insulin resistance, which results in a vicious circle116.  
 In relation to lipid metabolism, adiponectin stimulates fatty acid oxidation 
and reduces TG level113,228. Maternal adiposity is an important risk factor for the 
development of GDM, and more insight on the link between adiposity and glucose 
intolerance is required120,227. Low levels of serum adiponectin associate with 
reduced lipid oxidation, impairment of insulin signalling with insulin resistance and 
stimulation of hepatic gluconeogenesis113. Therefore, measurement of adiponectin 
along with other biomarkers may serve as early predictors of GDM (early in 
pregnancy). IVF therapy may influence adiponectin release in pregnancy, although 
this remains speculative based on the current literature.  
2.4.5. Gut Microbiota Markers 
 
The relationship between intestinal microbiota and metabolic health is very 
topical and of much interest. Changes in the gut microbiota may influence 
development of much 21st century chronic illness, including diabetes mellitus, 
cardiovascular disease and dyslipidemia229. A list of inflammatory and gut-related 
markers to assess glucose homeostasis, insulin resistance and early markers of 
subsequent GDM development is summarised in Table 2 (refer to section 2.3.3). 





of serum LBP strongly correlate with LPS, and associate with insulin resistance, 
obesity and T2DM131,229,231,232. Assessment of gut permeability during pregnancy 
(through both IVF- and spontaneously-conceived pregnancies) would form a novel 
focus for future research, and provide insight into possible links between IVF and 
future risk of GDM.  
 
Table 4: Summary of Effects of Oral Contraceptives, Spontaneous 








Effect of IVF 
therapy with 
pregnancy 
Fasting Glucose ↑ No change during first 
trimester 
↑ 
Fasting Insulin ↑ No change during first 
trimester 
↑ starting from 
first trimester 
HOMA_IR ↑ ↓ or no change during 
first trimester 
↑ starting from 
first trimester 
Lipid Profile ↑ ↑ ↑↑ 
TSH ↑ No change or ↓ during 
first trimester 
No change 
Adiponectin No data No change during first 
trimester 
↓ 
LBP No data No change during first 
trimester 
↑ 
HOMA-IR: homeostatic model assessment of insulin resistance; TSH: thyroid-










































3.1.  Rationale 
 
Previous studies have focused on risk of obstetric complications and foetal 
outcomes in IVF-conceived pregnancies, and the effect of oral contraceptives on 
some metabolic parameters. However, limited knowledge is available in relation to 
the safety of IVF hormonal therapies on maternal metabolic, endocrine and 
inflammatory status, and the relationship to the known diabetogenic and 
atherogenic effects of pregnancy. As stated earlier, glucose and insulin levels do 
not normally change in early pregnancy. Increased insulin resistance and 
requirement occur during mid-gestation and more toward late gestation88. Given 
that IVF hormones are thought to play an important role in glucose homeostasis 
(tested on mice), physiological changes of pregnancy are expected to occur earlier 
in IVF-conceived pregnancy as a result of exogenous IVF hormones combined with 
those of pregnancy. Change in glucose homeostasis at 12 weeks was the primary 
outcome of this study and with the speculations that:  
1.     Baseline levels of glucose and insulin levels do not differ between the 
two groups (pregnant and non-pregnant) 
2.      Glucose and insulin levels do not differ at 4 weeks (as both groups 
receive the same IVF hormonal therapy) 
3.      Glucose and insulin levels differ at 12 weeks given that non-pregnant 
women will have stopped hormonal treatment and are not pregnant (levels 
go back to baseline). 
The secondary outcome of this study was related to the change in insulin 
sensitivity at 12 weeks compared to baseline levels and between groups. Other 
secondary outcomes included changes in lipid and thyroid profiles, as well as, in 
inflammatory and microflora-related markers at 12 weeks. 
This research will enhance the understanding of the short-term effect of IVF 
hormonal therapy on the metabolic, cardiovascular, endocrine and inflammatory 
systems, which include glucose and insulin homeostasis, lipid profile, gut 
microflora and thyroid function. The study will also provide insight into early risk 





of potential predictors of GDM. 
3.2.  Study Objectives 
 
1. To explore the short-term effects of IVF hormonal therapy on maternal metabolic 
and inflammatory status, including:  
i. Risk of glucose intolerance and insulin resistance  
ii. Risk of other metabolic, endocrine and inflammatory disturbances (including lipid 
profile, gut microflora and thyroid function) 
2. To identify possible early predictors of GDM and other metabolic-related 
adverse outcomes in IVF-conceived pregnancies. 
 
3.3. Hypothesis  
 
Null hypothesis (H0): at 12 weeks, changes in glucose and insulin levels (from 
baseline), lipid profile, thyroids and inflammatory markers in pregnant women are 
equal to changes in non-pregnant women. 
Alternate hypothesis (H1): at 12 weeks, change in glucose and insulin levels (from 
baseline), lipid profile, thyroids and inflammatory markers in pregnant women is 
not equal to changes in non-pregnant women. 
 
3.4. Research Questions 
 
1. Do IVF hormonal therapies impair glucose homeostasis and insulin 
sensitivity starting from the first trimester of pregnancy? 
2. Do IVF hormonal therapies impair other endocrine, cardio-metabolic and 
inflammatory parameters (such as lipid and thyroid profiles)? 
3. Given the preconception measures and early gestational screening in IVF-





















Section 2: Methods and Analysis 
 
 















4.1. Ethics and Consents 
 
The study was initially reviewed by Warwick Medical School upon 
enrolment in the PhD program. Approval to conduct the study was first granted by 
the University of Warwick’s Biomedical and Scientific Research Ethics Sub-
Committee (BSREC) (REGO-2018-2232) (Appendix 1). The study protocol was 
also reviewed by the two main health authorities in the UAE, as recruitment of 
participants occurred from three centres located in Dubai, Abu Dhabi and Al Ain. 
Dubai Health Authority (DHA) “University Students Application to Conduct 
Research” recognised centres and “Dubai Scientific Research Ethics Committee” 
(DSREC) (DSREC-11/2017_09) approved the study for the Fakih IVF Dubai 
branch (Appendix 2) and the Medical Research Department at the Ministry of 
Health (MOH) (HCQ-190-18) for Abu Dhabi and Al Ain Fakih IVF branches 
(Appendix 3). The study was registered under the name of Warwick University at 
ClinicalTrials.gov (NCT03426228). Ethical approvals were renewed and revised 
yearly by both DHA and MOH.  
Informed consent was obtained from each participant who agreed to 
participate in the study before undergoing IVF therapy (Appendix 5). Prior to 
informed consent, there was provision of an explanation about the nature and 
purpose of the study to all potential participants. Confidentiality and anonymity of 
all participants was maintained throughout the study, and this was made clear to 
them. All participants could withdraw from the study at any time. In case a patient 
decided not to participate in the study, this decision did not affect ongoing clinical 
care in any way. There was also clear explanation of this information to all potential 
participants.  
 
4.2. Study Design 
 
The presented research is a longitudinal quantitative cohort study, whereby 
blood samples were collected at different stages during IVF therapy. The reference 
point is prospective and the nature of the investigation is correlational 





4.3.  Study Setting 
 
The study took place at Fakih IVF Clinics in Dubai, Abu Dhabi and Al Ain 
branches in the UAE. Fakih IVF is the leading and most advanced infertility clinic 
in the UAE, where approximately 4000 IVF cycles are conducted annually. At 
Fakih IVF, pre- and post-fertility treatments and in-house obstetric facilities are 
provided, including blood tests, scans, IVF procedures (e.g. laparoscopy, egg 
retrieval, embryo transfer, microdissection) and in-house genetic testing. Most 
patients are followed up to the point of delivery.  
4.3.1. Participant Recruitment and Screening  
 
On the first visit with the IVF specialist, patients discuss the fertility 
treatment that is appropriate for them. Female reproductive hormone tests are 
conducted to help identify the type of fertility protocol to apply. Hormonal assays 
included AMH, FSH, LH, oestrogen, progesterone and prolactin. Thyroid-
stimulating hormone (TSH) and HbA1c are also tested to screen for thyroid 
dysfunction and dysglycaemia respectively. Any fertility treatment would usually 
start on the second day of the menstrual cycle (labelled as CD2). Hence, patient 
comes on their second day of their following cycle if she agreed with her doctor 
to start the IVF therapy. On a daily basis, all CD2 files for the next day were 
reviewed to check if they will be undergoing an IVF therapy and if so, their 
eligibility for the study. In case the patient was eligible (first screening steps, non-
diabetic and normal thyroid function on file), the main investigator would call her 
to introduce the study and the purpose of the tests. If the patient was willing to 
participate, she was asked to undergo an overnight fast of 8 hours on the day of 
her appointment.       
Consent forms were signed on their first day of the IVF treatment; 
anthropometrics and medical history questionnaire were completed as well 
(Appendix 4). The nurse in the phlebotomy room was informed to add the 
following hormonal tests: lipid profile, fasting glucose and insulin, TSH and 
HbA1c. The list of tests and the consent form were attached in patients’ chart; a 





5 and 6). 
 
4.4. Study Population 
4.4.1. Inclusion and Exclusion Criteria  
 
Adult obese (BMI: 30–38 kg/m2) and non-obese (BMI: 18.5–29.9 kg/m2) 
women (≤39 years of age), presenting with any infertility concern (such as PCOS, 
fallopian tube obstruction, endometriosis, fibroids, male factor), with or without 
insulin resistance or a combination of these factors were eligible participants for 
the study. Patients were excluded if they presented with diabetes (confirmed by 
impaired or abnormal fasting glucose and/or HbA1c), and/or abnormal thyroid 
function. Patients were also excluded if they had any pre-existing serious medical 
concerns, such as cancer, hepatic, haematological, renal (e.g. impaired kidney 
function), pulmonary, cardiovascular (e.g., stroke, myocardial infarction) 
dysfunctions. An additional exclusion factor included medications that may affect 
glucose homeostasis, thyroid and/or lipid profile. This included glucose-lowering, 
thyroid medications, growth hormones, oral steroids, anti-inflammatory, 
immunosuppressant, bronchodilators and antiarrhythmic drugs233,234. Advanced 
pre-gestational age and obesity are one of the main risk factors for GDM. These 
factors also confound egg quality and quantity. It was important therefore to 
minimise the confounding effect of age on metabolic outcomes, through adopting 
an upper age limit of 39 years, given that most patients who are seeking IVF 
treatment at the clinic are usually under the age of 39 years, and still have good 
ovarian reserve and response.  
4.4.2. Study Groups 
 
➢ Pregnant group: received IVF therapy and tested positive for pregnancy 
at 4 weeks, and continued taking IVF hormonal therapy until 12 weeks of 
pregnancy. 
 
➢ Non-pregnant: received IVF therapy and tested negative for pregnancy at 





4.5. Sampling Technique 
 
The non-probability convenience sampling method was used to recruit 
participants for the study. Patients who were to start a fresh IVF treatment at any 
of the IVF Clinic branches (Dubai, Abu Dhabi or Al Ain) and meeting the inclusion 
criteria were eligible to participate.  
 
4.6. Sample Size Calculation 
 
During the first trimester of a spontaneously-conceived pregnancy, glucose 
and insulin levels are thought not to differ from non-pregnant levels. Fasting insulin 
level starts increasing in the second and third trimesters, and follows a reciprocal 
relationship with steadily diminishing insulin sensitivity81,88. In this study, the 
diabetogenic effect of pregnancy on glucose and insulin homeostasis is expected to 
occur earlier (starting from the first trimester) as an effect of IVF hormonal therapy. 
If the proportion of attribute (≈45% infertility couples) in this study is set to 
be 𝑝 and the standard deviation of changes at 12 weeks from baseline is 𝜎, to detect 
a mean difference of size 𝛿 with (1 − 𝛽)% power at 𝛼 significance level, the 









It follows that the sample size for non-pregnant women is (
1−𝑝
𝑝
) 𝑛. The hypothesis 
was tested at 5% significance level, corresponding to 𝑧𝛼/2 = 1.96 and 80% power 
to 𝑧𝛽 = 0.84.  
Significant change in glucose and insulin levels can be expected at the first 
trimester with IVF-conceived pregnancy (as an effect of exogenous hormones). 
Such information is however not available in the literature, since insulin 
measurements are only tested at around the second trimester when it usually starts 
changing, and these studies were conducted in spontaneous pregnancy and not IVF-
conceived pregnancy. Given that the ratio 𝛿/σ cannot be determined, a standardised 





• 0.3 corresponding to a small difference 
• 0.5 corresponding to a moderate difference 
• 0.7 corresponding to a big difference 
It will be very difficult to convince a non-pregnant participant, who spent 
10,000$ on the treatment which failed to come back after 12 weeks for a blood test. 
Consequently, the number of non-pregnant participants was narrowed to a ratio of 
2:1 pregnant to non-pregnant, and which corresponded to p=0.67.  
In order to detect a moderate difference (standardised difference=0.5), with 
80% power, at significance level of 0.05 and a ratio of 2:1 for pregnant to non-
pregnant women, the sample size consisted of 96 pregnant and 48 non-pregnant 
women. According to the latest statistics, pregnancy success rate post-egg retrieval 
is about 30% and this declines with age235,236. This success rate is comparable to 
the rate reported by Fakih IVF Clinics. Therefore, 275 participants were recruited 
initially to end up with 96 clinically confirmed pregnant. 
 
4.7. Data Collection 
4.7.1. IVF Therapy Protocol  
 
 The IVF protocol consists of three phases: egg maturation preparation, egg 
and sperm collection and embryo transfer. The IVF intervention type that was used 
with the study participants was the “antagonist protocol”, which relies on 
administering agents to prevent premature ovulation (i.e. gonadotrophin-releasing 
hormone antagonist)237 (Figure 1 and 2).      
 On day 2 or 3 of the menstrual cycle, ovarian stimulation began with daily 
administration of FSH alone or combined with LH injection, depending on baseline 
hormonal levels, to stimulate follicle growth and development into eggs. Follicle 
growth (size and numbers) were monitored throughout the stimulating phase with 
frequent ultrasound and hormonal blood tests (FSH, LH, oestrogen and 
progesterone hormones). IVF therapy was adjusted accordingly. Ovarian 
stimulation lasted from 8 to 12 days. On day 6 of stimulation, gonadotrophin-





to block endogenous GnRH activity, which normally stimulates FSH and LH 
release from the pituitary gland. Under normal physiological conditions, FSH 
influences egg growth and maturation, and stimulates oestrogen production. LH 
triggers the late stage of egg maturation and ovulation, and stimulates progesterone 
production from the ovaries. The ovaries normally secrete oestrogen and 
progesterone post-ovulation. GnRH administration enables better control of the 
reproductive environment (through suppression of endogenous hormones), and 
prevents premature ovulation during IVF therapy41. Similar in function to LH, a 
human chorionic gonadotrophin (hCG) hormone “trigger” injection is administered 
36 to 40 hours before the schedule of egg retrieval to induce final egg maturation 
and to trigger the rupture of eggs from ovarian follicles41. At this stage, there is 
discontinuation of all other IVF-related hormones. On the day of egg retrieval, also 
called ‘oocyte pick-up’ (OPU), patients are required to come having fasted for 8 
hours. OPU is performed under sedation and using an ultrasound guided needle. 
The number of eggs collected depends on the number of follicles which responded 
to the stimulation; on average, 8 to 15 eggs are retrieved238. After OPU, patients are 
prescribed progesterone and oestrogen therapies (‘luteal therapy’) to help prepare 
the uterine lining for embryo implantation and support early pregnancy. The IVF 
hormones were administered in different forms: intramuscularly, orally and 
vaginally. The dose and type of oestrogen and progesterone depended on the patient 
history, stage of pregnancy and purpose (for instance if bleeding or spotting is 
present, vaginal administration may be appropriate).     
 The collected semen sample is injected into retrieved eggs under 
microscope, and following the intracytoplasmic sperm injection (ICSI) method. 
The ICSI method increases the chances of successful fertilisation and consists of 
injecting a single sperm directly into the cytoplasm of an egg41. Embryos are 
assessed based on morphology and rate of cells division to advance from zygote to 
blastocyst. Genetic testing (GT) of embryos is conducted on day 3 or 4 post-OPU. 
This includes pre-implantation chromosomal screening and/or pre-implantation 
genetic diagnosis. The latter helps screening for inherited diseases. Embryo transfer 





would be cancelled when ovarian hyperstimulation syndrome (OHSS) occurred. 
OHSS is one of the complications of ovarian stimulation when undergoing ART, 
and may necessitate embryo freezing and re-scheduling of ET for the next 
menstrual cycle in severe OHSS cases.    
 Pregnancy success and the risk of multiple pregnancies depend on the 
number of eggs transferred238. On day 8 post-embryo transfer, the first β-HCG test 
(also known as pregnancy test) is conducted and repeated on day 10 and if needed 
on day 12.  In a successful pregnancy, serum β-HCG usually doubles every 48 
hours. An ultrasound scan is scheduled two weeks post-embryo transfer to assess 
for pregnancy viability and the presence of a sac. At 8 weeks of gestation, foetal 
heartbeat is usually detected with ultrasound. Serum oestrogen and progesterone 
levels are measured regularly (until the first ultrasound) to adjust the dose of IVF-
hormonal therapy. Hormonal therapies were discontinued (at 4 weeks) in all cases 
of negative, ectopic or biochemical pregnancy. Otherwise, participants were 
instructed to continue taking hormonal therapies until around week 12 of 
pregnancy. Biochemical pregnancy (also called early miscarriage) implies a 
pregnancy confirmed by a positive pregnancy test (i.e. β-HCG), but no sac is visible 
on ultrasound. Ectopic pregnancy also implies a positive β-HCG but the level 
increases at slower rate. The latter is considered as a complication of pregnancy, 
whereby the embryo implants outside the uterus (such as in the fallopian tube), 
resulting from the amount of fluid injected with the embryo not being minimal, or 
when the location of the embryo transfer is closer to the fallopian tubes239. A 
clinical pregnancy is confirmed by both high serum β-HCG level and ultrasound 








Figure 1. In Vitro Fertilisation Protocol Steps240 
 
4.7.2. UAE Regulations 
 
In the UAE, it is strictly prohibited to have egg or sperm donors, whilst 
gender selection is allowed (Article 10, p.7)241. The optimal number of embryos to 
transfer is determined based on the patient characteristic, age and medical history41. 
According to Health Authority Abu Dhabi (HAAD) regulations, patients with a 
favourable prognosis should be transferred no more than two embryos if under 35 
years of age, but no more than three if 37 years and older (Article 13, p.8)241,242. 
These guidelines are also compatible with the American Society for Reproductive 
Medicine (ASRM) regulations243. 
 
4.8. Study Protocol  
4.8.1. Study Stages 
 
After an overnight fast of 8 hours, there was collection of 10 ml of blood at 
four pre-defined time points during the IVF protocol: 
1. Phase 1– At baseline, egg maturation (starting IVF therapy) 





2. Phase 2 – Week 2 – Egg retrieval (OPU procedure)   
3. Phase 3 – Week 4 – At pregnancy test (β-HCG test) 
4. Phase 4 – Week 12 (one week after completing IVF hormonal 
therapy for pregnant group). 
4.8.2. IVF Therapies  
 
Ovarian reserve and age of the women are important factors to consider 
when defining the type of IVF treatment and dosage of IVF hormones to take (Table 
5). Anti-müllerian hormone (AMH) and FSH levels and antral follicle count 
(through transvaginal ultrasound) determine ovarian reserve. AMH is a hormone 
secreted by the cells of growing follicles of the ovaries244. High FSH level, low 
AMH or low follicle count are all indicators of low ovarian reserve and may predict 
low chances of pregnancy245. In that case, higher dose of IVF hormones may be 
required. Older women may require higher doses of stimulating hormones, as they 
tend to have a lower response and a higher risk of miscarriage compared to younger 
women1,41.  
For pregnant group, the final blood sample (phase 4) was collected a week 
post-discontinuation of hormonal therapies at around week 12 of pregnancy (half-
life of exogenous hormones is about 15–50 hours), to ensure sufficient time for 














Table 5: Description of IVF Hormonal Therapy 
 
















rupture of follicles and 
helps in controlling the 





Triggering  GnRH agonist or 
recombinant hCG 
Similar effect to LH 
surge for final 
maturation of eggs, 36 








to support early 
pregnancy and 




mg/d;                  
Tablets: 10 mg/ 
TID;                   
Vaginal: 100 




Synthetic oestrogen to 
prepare uterine lining 
2 mg/TID 
FSH: follicle-stimulating hormones; LH: luteinizing hormone; GnRH: gonadotrophin-
releasing hormone hCG: human chorionic gonadotrophin; TID: three times a day; BID: 
twice a day  
 
4.8.3. Intervention Plan  
During the stimulation period, patients are required to visit the clinic every 
two days for hormonal blood tests to monitor their response to the treatment and to 
take their injections, and then at 8 and 10 days post-embryo transfer for the 





8 weeks with heartbeat detected), they were scheduled for a prenatal follow-up 
every three weeks. Hormonal profile is measured at each of their visits to adjust the 
dose of IVF stimulating agents (i.e. FSH, LH, progesterone and oestrogen).  
 
 Figure 2: Study Stages and IVF Therapy Intervention 
 
 










































*Green highlight represents stage where non-pregnant vs. pregnant women groups were 
distinguished; hCG: human chorionic gonadotrophin; FSH: follicle-stimulating 
hormones; LH: luteinizing hormones; GnRH: gonadotrophin-releasing hormone; β-








4.9. Choice of Biomarkers and Measuring Techniques 
 
The standard blood test panel was conducted and included fasting glucose 
and insulin, HbA1c, lipid profile and thyroid level. In addition, after comparing the 
different well-recognized methods to measure glucose homeostasis and insulin 
resistance, HOMA-IR was selected for early gestation assessment (up to 12 weeks). 
This method (formula-based) provides a highly reliable estimates of insulin 
resistance and which also correlates with estimates by the “gold standard” 
euglycaemic clamp technique216 (refer to Table 3). Additionally, HOMA-IR 
method is validated in pregnancy and even with the presence of gestational 
obesity248. It is also simple, practical and safe in pregnancy. The OGTT test was 
conducted around 28 weeks of gestation to diagnose GDM. In the present study, 
the 2-hour OGTT glucose cut offs suggested by the International Association of 
Diabetes and Pregnancy Study Groups were used for GDM diagnosis, with two 
abnormal levels from the following: glucose fasting ≥92 mg/dL (5.1 mmol/L), ≥180 
mg/dL (10 mmol/L) for 1-hour and ≥153 mg/dL (8.5 mmol/L) for 2-hours197. 
In regards to inflammation, different markers were evaluated and the 
following criteria were taken into account: cost, test acceptability in pregnancy, 
earliest possible indicator of any change, and availability and accessibility of 
measuring kits in the UAE (refer to Table 2). Given the well-demonstrated direct 
association of adiponectin with inflammation and insulin resistance, this parameter 
was selected for the present study as a potential early marker of changes in glucose 
homeostasis and inflammation. Additionally, most studies focused on the 
association between adiponectin and risk of T2D113. Further insight into the 
association between adiponectin and onset of GDM is hence needed.  
In relation to gut endotoxemia and related inflammatory biomarkers (refer 
to Table 2), LBP was thought to be appropriate in reflecting changes in both 
mechanisms. Strong evidence have suggested using LBP as a surrogate marker of 
endotoxemia and resultant inflammation in place of LPS. Consequently, given its 
high stability, LBP biomarker was selected in this study as a potential early 
indicator of change in inflammation and gut microflora during IVF therapy and in 





regards to the effect of hormonal therapy on LBP and further studies on its 
predisposition to onset of GDM are required. 
In addition, well-documented and appropriate anthropometric and 
metabolic cut-offs were also tested at 12 weeks to assess participants at high risk 
of GDM. These parameters included age ≥35 years1,7, BMI ≥30 kg/m2 from NICE 
guidelines25, BMI ≥35 kg/m2 by British Fertility Society24, HbA1c ≥5.7% (39 
mmol/mol)200,203, TSH ≥2.5 µIU/mL183, TG ≥137 mg/dL (≥1.55 mmol/L)223, HDL-
C ≤85.5 mg/dL (≤2.21 mmol/L)119, log TG/HDL-C ≥0.099226 and adiponectin ≤6.4 
μg/mL113,227. A narrowed ethnicity classification into two main groups (Arabs vs. 
non-Arabs) was also tested given the higher prevalence of GDM in the Arab 
community192,249.  
 
4.10. Blood Tests 
  A trained nurse was in charge of measuring anthropometrics and clinical 
parameters (e.g. weight and blood pressure), in addition to taking fasting blood 
samples (Table 7). The socio-demographics, medical and pregnancy histories of 
each patient were recorded in their file. Blood tests were conducted at Fakih IVF 
(in the phlebotomy room) and transferred to the lab (in-house) for analysis. Tests 













Table 7: List of Blood Tests at Each Stage of the Study 
 
 















hormones: FSH, LH, 
oestrogen, 
progesterone 
√ √ √  
HbA1c √   √ 
Fasting glucose √ √ √ √ 
Fasting insulin √ √ √ √ 
TSH √   √ 
Fasting lipid profile √   √ 
Adiponectin √   √ 
LBP √   √ 
β-HCG pregnancy  √  √  
Body weight  √   √ 
*Green highlight represents stage where non-pregnant vs. pregnant women groups were 
distinguished; FSH: follicle-stimulating hormones; LH: luteinizing hormone; HbA1c: 
glycated haemoglobin A1c; TSH: thyroid-stimulating hormone; LBP: 




Within 24 hours of blood collection, participants received a call from the 
clinic to provide them with an overview of their results. If there was any abnormal 
result with clinical significance (such as new diagnosis of diabetes), participants 
and the physician in charge were promptly informed by the principal investigator 
(Ayla Coussa). Appropriate clinical management (including any additional 
investigations) would be arranged within the clinical setting at Fakih IVF Centres 





4.12. Risks and Benefits of Participation 
 
This study did not present any risk to participants, since no additional 
injections were required and tests were analysed from the same serum sample used 
for standard IVF therapy. The study did not affect in any sense the flow of fertility 
treatment. Responsibility for any risks of the tests throughout the treatment period 
was covered by the IVF Clinic. Findings from this study have the potential to reduce 
the prevalence of complications and metabolic disturbances in relation to IVF-
pregnancy outcomes through identification of early predictors of onset of metabolic 
dysfunction. A copy of all blood test results was provided to participants at the end 
of the study. 
 
4.13. Data Analysis  
4.13.1. Assays  
4.13.1.1. Hormones  
 
Female hormones (AMH, FSH, LH, oestrogen, progesterone, and β-HCG) 
and TSH levels were measured with the electrochemiluminescence immunoassay 
(ECLIA) using Cobas E analysers (Elecsys 2010, E170), which was supplied by 
Roche Diagnostics (Indianapolis, USA).  
4.13.1.2. Glucose Homeostasis and Insulin Resistance 
Fasting plasma insulin (FPI) was also measured by ECLIA kit using Cobas 
E immunoassay analysers (Elecsys 2010, E170) from Roche Diagnostics 
(Indianapolis, USA). Fasting plasma glucose (FPG) was measured by enzymatic 
reference method with hexokinase-glucose-6-phosphate dehydrogenase using 
Roche/Hitachi Cobas C systems (Roche Diagnostics, Indianapolis, USA). Both 
fasting FPI concentration (µIU/mL) and FPG (mg/dL) were used in the homeostatic 
model assessment (HOMA) to quantify insulin resistance (IR) and assessment of 
glucose homeostasis. HOMA-IR was calculated as follows216,217: HOMA-IR = (FPI 





4.13.1.3. Lipid Profile  
 
Total cholesterol (T-Chol), triglycerides (TG) and high-density lipoprotein 
cholesterol (HDL-C) were measured by homogenous enzymatic colorimetric 
method with Roche/Hitachi Cobas C systems (Cobas C 311/501), supplied by 
Roche Diagnostics (Indianapolis, USA). Low-density lipoprotein cholesterol 
(LDL-C) was determined using the Friedewald formula250:  LDL-C = (T-Chol) – 
(HDL-C) – (TG/5).  
4.13.1.4. Adiponectin and Lipopolysaccharide binding protein (LBP)  
Enzyme linked immunosorbent assay was used to measure plasma LBP 
concentration by human LBP ELISA kit (catalog number E-EL-H2289-96T) and 
serum adiponectin by human ADP/Acrp 30 ELISA kit (catalog number E-EL-
H5811-96T), from Elab Science (Texas, USA). The specifications of LBP ELISA 
kit include the following: sensitivity of 1.88 μg/mL, detection range of 3.13–200 
μg/mL and <10% coefficient of variation (Intra-assay CV, low: 3.52%; high: 
6.49%; Inter-assay CV, low: 4.66%; high: 5.32%). Adiponectin ELISA kit 
specifications are: sensitivity of 0.10 μg/mL, detection range was 0.16–10 μg/mL 
and <10% coefficient of variation (Intra-assay CV, low: 11.04%; high: 12.77%; 
Inter-assay CV, low: 7.81%; high: 8.40%). Optical density was measured by 
spectrophotometer at a wavelength of 450 ± 2 nm (optical density value is 
proportional to concentration of human LBP and to concentration of human 
ADP/Acrp 30). 
4.13.2. Statistical Analyses  
4.13.2.1. Effects of IVF Therapy  
 
Data analysis was performed with the Statistical Package for 
the Social Sciences (SPSS) software version 21.0 for Windows (SPSS, Chicago, 
IL). Parameters normality was first visually tested with the histogram 
configuration, and confirmed with the Shapiro-Wilk test. Most of the measured 
parameters were not normally distributed. For non-normally distributed parameters, 





using median and interquartile range (IQR). IQR represents the difference between 
75th and 25th percentiles or between upper and lower quartiles (IQR = Q₃ − Q₁).  
Non-parametric Mann-Whitney U test for two independent samples was 
used to compare the two groups pregnant vs. non-pregnant, at baseline and at 12 
weeks. Non-parametric Wilcoxon test for two related samples was conducted to 
assess changes at baseline vs. post-IVF treatment (12 weeks) within groups 
(pregnant or non-pregnant). Bivariate correlation was used to determine 
correlations between the different anthropometric and metabolic parameters at 
week 12. Data from the two groups were analysed separately. Linear regression 
was used for assessment of association of change in glucose level at 12 weeks 
(dependent variable) with change in other anthropometric and biochemical 
parameters, separately for each group. Changes in glucose and insulin levels (and 
the resulting HOMA-IR) throughout IVF therapy (baseline, 2, 4 and 12 weeks) 
were determined with the mixed model for repeated measures test.  
4.13.2.2. Anthropometrics and Biomarkers of GDM 
 
In the pregnant group, the Mann-Whitney U test for two independent 
samples was used to compare data at baseline with 12 weeks, for comparison 
between women who later developed GDM to the non-GDM group. Changes at 
baseline, 4 and at 12 weeks were assessed by non-parametric Wilcoxon test (two 
related samples) within groups (future GDM or non-future GDM women). Data are 
summarised using median and interquartile range (IQR). 
Chi-square and fisher’s exact tests were used to assess the association of 
anthropometric characteristics and pregnancy outcomes (categorical) with GDM. 
Ethnicity was stratified into seven groups: Middle East, Gulf, Europe, North 
America, South Asia, East Asia and Africa. Predictors of GDM were assessed using 
binary logistic regression, adjusting for the following variables: age and history of 
PCOS. In addition, chi-square was used to test the validity of documented and 
selected appropriate anthropometric and metabolic cut-offs (levels at 12 weeks) to 
predict GDM: age ≥35 years, BMI ≥30 kg/m2, BMI ≥35 kg/m2, HbA1c ≥5.7% (39 





mg/dL (≤2.21 mmol/L), log TG/HDL-C ≥0.099, adiponectin ≤6.4 μg/mL and 
belonging to the Arab ethnicity. The significance level was set at p<0.05 with 95% 
confidence interval (CI).    
4.13.2.3. Pregnancy and Foetal Outcomes   
 
Chi-square and fisher’s exact tests were also used to measure the association 
of pregnancy and foetal outcomes (categorical) with delivery by caesarean section.  
Predicting delivery by caesarean section with maternal and foetal 
characteristics were assessed using binary logistic regression, adjusted for BMI at 







































Section 3: Results and Discussion 
 
 

















5.1. Participants Enrolment 
 
A total of 702 women were pre-screened, 693 screened of whom 673 
participants were eligible for enrolment in the study. Out of the 673 only 354 
participants had embryo transfer, with the remaining 221 cycles were converted to 
freezing, 98 were cancelled due to poor quality, low number of eggs and/or genetic 
abnormalities. Post-embryo transfer, 191 participants presented with a clinically 
confirmed pregnancy, 153 with a negative β-HCG and 10 experienced either a 
biochemical or ectopic pregnancy. At week 12, there were 52 drop-outs whereby 
some of participants had already left the country before the 12 weeks tests and 
others withdrew consent due to failed pregnancy (Figure 3). Overall, 275 
participants completed the study, with 158 pregnant and 117 non-pregnant women. 
Ultimately, pregnancy outcomes included 34% multiple, 6% biochemical and 3% 
ectopic pregnancy, and 8% miscarriage. 
 





5.2. Metabolic, Endocrine and Inflammatory Outcomes 
 
Phenotypic characteristics of participants are shown in Tables 8, 9 and 10. 
Data are summarised as median (IQR). At baseline, there was no significant 
difference between the two groups (pregnant and non-pregnant following IVF) in 
relation to anthropometric, endocrine (including female hormonal profile), and 
metabolic parameters (Table 10). At preconception, participants had a median age 
of 32 (6) years, BMI of 25.4 (6.9) kg/m2, HbA1c of 5.2 (0.52) % (33 mmol/mol) 
and TSH of 1.82 (1.4) µIU/mL. Age (>35 years) did not affect IVF outcome. 
Phenotypic characteristics of pregnant women are presented in Table 8. 
Compared with baseline values, there were significant reductions at 12 weeks in 
fasting glucose (86.15 to 82.19 mg/dL or the equivalent to 4.8 to 4.6 mmol/L), 
HbA1c (5.3 to 5.08% or the equivalent to 34 to 32 mmol/moL) and TSH (1.7 to 1.4 
µIU/mL), with p<0.001 for all parameters; whilst serum insulin level was 
unchanged (p=0.23). Lipid profile parameters increased significantly at 12 weeks 
compared with baseline values by: 12% in T-Chol (177.5 to 199.5 mg/dL or the 
equivalent to 4.60 to 5.15 mmol/L), 72% in TG (73.5 to 126.78 mg/dL or the 
equivalent to 0.83 to 1.43 mmol/L) and 18% in HDL-C levels (55.3 to 65.1 mg/dL 
or the equivalent to 1.43 to 1.68 mmol/L). BMI also increased significantly (24.8 
to 25.7 kg/m2, p<0.001) at 12-weeks compared with baseline. Compared to baseline 
concentrations, insulin, adiponectin, LBP, and HOMA-IR all remained unchanged 
when measured at 12 weeks of pregnancy.  
Phenotypic characteristics of non-pregnant women are presented in Table 
9. Compared with baseline values, at 12 weeks fasting plasma glucose level 
increased by 2% (86.04 to 87.62 mg/dL or the equivalent to 4.77 to 4.86 mmol/L), 
serum insulin by 7% (8.72 to 9.37 µIU/mL) and HOMA-IR by 10% (1.9 to 2.1); 
with all p<0.01. Lipid profile parameters also increased significantly at 12-weeks: 
T-Chol by 3% (169.5 to 174.9 mg/dL 4.38 to 4.52 mmol/L), TG by 18% (71.0 to 
83.7 mg/dL or the equivalent to 0.81 to 0.95 mmol/L) and HDL-C by 4% (52.0 to 
54.11 mg/L or the equivalent to 1.34 to 1.40 mmol/L); with p<0.001 for all lipid 
parameters. Adiponectin, LBP and TSH levels remained unchanged at 12-weeks 





0.7% (25.6 to 25.8 kg/m2; p=0.002) at 12-weeks compared to baseline value. 
When comparing both pregnant and non-pregnant groups, the small 
increment in weight (2%) was similar in both groups (Table 10). Fasting glucose 
and HbA1c varied significantly between the two groups (p<0.001), with lowered 
glucose level in clinically-confirmed (positive) pregnancy and increased with 
negative pregnancy (Graph 1A). Insulin level and HOMA-IR did not differ between 
groups at 12 weeks (Table 8; Graph 1B and 1C). The increment in lipid parameters 
occurred regardless of pregnancy status, but with a higher increase from baseline 
in positive pregnancy (p<0.001). TSH level was only significantly altered during 
pregnancy and which is likely associated with the observed difference between the 
two groups (p<0.0001). Regardless of pregnancy status, adiponectin and LBP 

































Table 8. Anthropometrics, Metabolic and Endocrine Parameters at 
Baseline and 12 Weeks of IVF Therapy for Pregnant Women 
 
Variables 
 (n=158) p 
value  Baseline  12 Weeks 
Age (years)        32.0 (7.0)    
Weight (kg)                    65.5 (18.95)  66.9 (15.9) <0.001 
Body mass index (kg/m2)  24.8 (7.30)  25.57 (6.90 <0.001 
Female Hormones                      
FSH (IU/L)           6.46 (2.51)    
LH (IU/L)                                     5.99 (3.16)    
Ratio FSH/LH  1.10 (0.60)    
Estrogen (pg/mL)                  41.9 (24.2)  *412.15 (857.10) <0.001 
Progesterone (ng/mL)  0.23 (0.23)  *41.07 (37.61) <0.001 
Metabolic and Endocrine      
Fasting glucose (mg/dL)             86.15 (8.0)  82.19 (7.19) <0.001 
Fasting insulin (µIU/mL)                        8.84 (6.81)  9.45 (6.95) 0.23 
HbA1c (%)                                 5.3 (0.58)  5.08 (0.53) <0.001 
HOMA-IR                                         1.95 (1.52)  2.00 (1.60) 0.75 
T-Chol (mg/dL)                                               177.5 (44.95)  199.5 (44.35) <0.001 
TG (mg/dL)                                         73.5 (44.0)  126.78 (60.3) <0.001 
LDL-C (mg/dL)                                          103.0 (38.95)  103.2 (32.43) 0.82 
HDL-C (mg/dL)                                  55.3 (15.94)  65.1 (18.3) <0.001 
TSH (μIU/mL)                    1.71 (1.29)  1.36 (1.10) <0.001 
ŦAdiponectin (μg/mL)   8.87 (1.86)  8.66 (2.41) 0.29 
ŦLBP (μg/mL)  62.96 (78.83)  45.18 (71.82) 0.71 
Data  presented in median and interquartile range (IQR; IQR=Q3-Q1); Ŧn=42 
pregnant; p<0.05 vs. at 12 weeks of IVF therapy, by two-related-samples test; FSH: 
follicle-stimulating hormone; LH: luteinizing hormone; HbA1c: glycated 
haemoglobin A1c; HOMA-IR: homeostatic model assessment of insulin resistance; T-
Chol: total cholesterol; TG: triglycerides; LDL-C: low-density lipoprotein cholesterol; 
HDL-C: high-density lipoprotein cholesterol; TSH: thyroid-stimulating hormone; 















Table 9. Anthropometrics, Metabolic and Endocrine Parameters at 
Baseline and 12 Weeks of IVF Therapy for Non-pregnant Women 
 
Variables 
 (n=117) p 
value  Baseline  12 Weeks 
Age (years)        32.5 (7.00)    
Weight (kg)                    64.0 (13.97)  64.7 (15.05) 0.003 
Body mass index (kg/m2)  25.55 (6.15)  25.75 (5.73) 0.002 
Female Hormones                       
FSH (IU/L)           6.65 (2.47)    
LH (IU/L)                                      5.75 (2.70)    
Ratio FSH/LH  1.10 (0.50)    
Estrogen (pg/mL)                  41.04 (19.15)  *220.5 (197.90) <0.001 
Progesterone (ng/mL)  0.24 (0.20)  *20.96 (23.95) <0.001 
Metabolic and Endocrine      
Fasting glucose (mg/dL)             86.04 (10.0)  87.62 (8.34) <0.001 
Fasting insulin (µIU/mL)                       8.72 (6.41)  9.37 (5.4) 0.008 
HbA1c (%)                                 5.2 (0.50)  5.19 (0.47) 0.16 
HOMA-IR                                        1.9 (1.50)  2.1 (1.5) 0.003 
T-Chol (mg/dL)                                                169.5 (39.33)  174.9 (48.03) <0.001 
TG (mg/dL)                                         71.0 (41.98)  83.7 (35.15) <0.001 
LDL-C (mg/dL)                                          101.3 (44.0)  102.57 (38.83) 0.49 
HDL-C (mg/dL)                                 52.0 (18.82)  54.11 (14.30) <0.001 
TSH (μIU/mL)                    1.95 (1.46)  1.8 (1.05) 0.17 
ŦAdiponectin (μg/mL)   8.47 (2.17)  8.46 (1.94) 0.53 
ŦLBP (μg/mL)  55.60 (70.70)  41.29 (88.16) 0.29 
Data  presented in median and interquartile range (IQR; IQR=Q3-Q1); Ŧn=42 
pregnant; *Levels at 4 weeks; p<0.05 vs. at 12 weeks of IVF therapy, by two-related-
samples test; FSH: follicle-stimulating hormone; LH: luteinizing hormone; HbA1c: 
glycated haemoglobin A1c; HOMA-IR: homeostatic model assessment of insulin 
resistance; T-Chol: total cholesterol; TG: triglycerides; LDL-C: low-density 
lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TSH: thyroid-





















































Graph 1. Comparison of Glucose Homeostasis at Baseline and 12 Weeks of IVF 
Therapy between Pregnant and Non-pregnant Women (Graph A. Fasting Glucose 
Level; B. Fasting Insulin Level; C. HOMA-IR)                                                                                                                    
*p<0.05 at 12 weeks of IVF therapy; Ŧp<0.05 vs. pregnant; HOMA-IR: homeostatic 





5.2.1. Glucose and Insulin Homeostasis  
 
Glucose and insulin homeostasis results are summarised in Table 11 for the 
pregnant, Table 12 for non-pregnant women and comparing both groups in Table 
13 and Graph 2.  
In the pregnant group, compared to baseline values, glucose level measured 
at 2 (OPU), 4 (β-HCG) and 12 weeks (final) were signficanly lower (respectively, 
p=0.001, p=0.007 and p=0.001) (Table 11). Plasma glucose level did not differ 
between weeks 2 and 12 and between weeks 4 and 12. However, plasma glucose 
level at 4 weeks was significantly higher than at 2 weeks (p=0.004); hence glucose 
went down at 2 weeks, and then increased at 4 weeks and remained the same at 12 
weeks. The greatest difference in glucose level was between baseline and at 12 
weeks, which corresponds to a significant drop in glucose level by -4.40 mg/dL 
(0.2 mmol/L). In the pregnant group, serum insulin level increased significantly at 
4 weeks compared to values at OPU (delta change: 3.93 µIU/mL, p=0.01) and at 
baseline (delta change: 3.49 µIU/mL, p=0.03). Serum insulin level dropped by -
3.03 µIU/mL (p=0.06) at 12 weeks compared to 4 weeks. Serum insulin level 
differed the most at 4 weeks compared to baseline, and at 12 weeks it seems that 
the level goes back to baseline level. In the pregnant group, at 4 weeks HOMA-IR 
increased significantly compared to baseline (delta change: 0.76, p=0.03) and OPU 
(delta change: 0.91, p=0.01) but then decreased significantly at 12 weeks (delta 
change: -0.79, p=0.03).  
In the non-pregnant group, there was an initial drop in plasma glucose level 
at OPU by -4.01 mg/dL (-0.2 mmol/L) (p<0.001), followed by a progressive rise at 
4 weeks to baseline level, and reaching a significantly higher level at 12 weeks 
(delta change: 1.88 mg/dL or the equivalent to 0.1 mmol/L; p<0.001) (Table 12). 
Serum insulin level appeared to follow a reciprocal relationship to plasma glucose 
levels, with an initial increase in serum insulin level at 4 weeks by 2.85 µIU/mL 
(p<0.001) compared to baseline, and subsequent reduction at 12 weeks by -2.41 
µIU/mL (p<0.001). It seems that the OPU stage marked the point in IVF thereapy 





increment in HOMA-IR at 4 weeks is significant compared to OPU and baseline 
values (respectively, p=0.82 and p=0.60) and drops at 12 weeks to lower level than 
baseline (delta change: -0.14, p=0.03).  
 
When comparing the pregnant and non-pregnant groups, significant 
Table 11: Mean Difference in Glucose and Insulin Homeostasis at Each 
Stage of IVF Therapy: Baseline, 2 weeks (OPU), 4 weeks (β-HCG test) and 

















Baseline_2 weeks -3.96 <0.001 -0.04 0.35 -0.14 0.22 
Baseline_4 weeks -1.83 0.007 3.48 0.02 0.76 0.03 
Baseline_12 
weeks 
-4.40 <0.001 0.45 0.25 -0.02 0.80 
2 weeks_4 weeks 2.12 0.004 3.92 0.01 0.91 0.01 
2 weeks_12 
weeks 
-0.44 0.73 0.89 0.04 0.12 0.29 
4 weeks_12 
weeks 
-2.56 0.64 -3.03 0.06 -0.79 0.03 
OPU: oocyte pick-up; β-HCG: beta-human chorionic gonadotrophin pregnancy test; HOMA-
IR: homeostatic model assessment of insulin resistance 
Table 12:  Mean Difference in Glucose and Insulin Homeostasis at Each 
Stage of IVF Therapy: Baseline, 2 weeks (OPU), 4 weeks (β-HCG test) and 

















Baseline_2 weeks -4.01 <0.001 -0.54 0.27 -0.21 0.06 
Baseline_4 weeks -0.54 0.35 2.85 <0.001 0.60 <0.001 
Baseline_12 
weeks 
1.88 <0.001 0.44 0.11 0.14 0.03 
2 weeks_4 weeks 3.46 <0.001 3.40 <0.001 0.82 <0.001 
2 weeks_12 
weeks 
5.89 <0.001 0.99 0.03 0.36 0.001 
4 weeks_12 
weeks 
2.42 <0.001 -2.40 <0.001 -0.45 <0.001 
OPU: oocyte pick-up; β-HCG: beta-human chorionic gonadotrophin pregnancy test; HOMA-





changes in glucose and insulin homeostasis (including HOMA-IR) occur after 2 
weeks of IVF therapy (Table 13). At 4 weeks, the increment in glucose level was 
significantly higher in non-pregnant women (4%) compared to the pregnant group 
(3%) (p=0.01). Fasting glucose was also different between the two groups at 12 
weeks but changed in divergent directions depending on IVF outcome (pregnant or 
non-pregnant) (p<0.001) (Graph 2A). Insulin levels only differ between the two 
groups at 4 weeks of IVF hormonal therapy, with a much higher rise in insulin 
concentration for non-pregnant women (37% vs. 21%, p=0.01) and reverts back to 
baseline levels for both groups at 12 weeks (Graph 2B). Similarly, HOMA-IR only 
varied at 4 weeks between the two groups, with 44% increment in non-pregnancy 
and 18% in pregnancy (p=0.01). Overall change in glucose homeostasis followed 
similar pattern throughout the IVF stages for the two groups of pregnant vs. non-
pregnant up until 4 weeks and the magnitude of change was different (Graph 2C). 
Therefore, significant differences in glucose and insulin homeostasis between the 
pregnant and non-pregnant groups occured after week 2 of IVF hormonal therapy, 
































Graph 2. Changes in Glucose Homeostasis Throughout IVF Therapy between 
Pregnant and Non-pregnant Women (Graph A. Fasting Glucose Level; B. Fasting 
Insulin Level; C. HOMA-IR); 2 weeks (OPU: oocyte pick-up); 4 weeks (β-HCG 
pregnancy test); 12 weeks (Final) HOMA-IR: homeostatic model assessment of insulin 
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5.2.2. Anthropometrics, Metabolic and Endocrine Parameters 
Correlations  
5.2.2.1. Pregnant Women  
 
Correlations of the different parameters levels at 12 weeks are presented in 
Table 14A and B; oestrogen and progesterone levels were measured at 4 weeks and 
only FSH/LH ratio refers to baseline value.      
 For the pregnant group (Table 14A), age showed a positive weak but highly 
significant correlation with ratio FSH/LH (r=0.29, p=0.01) and T-Chol (r=0.24, 
p=0.01), but negatively correlated with insulin level at 12 weeks (r=-0.17, p=0.05). 
At 12 weeks, BMI positively corrrelated with levels of plasma glucose, serum 
insulin, and HOMA-IR (r=0.22, r=0.48 and r=0.49 respectively, with p=0.01). BMI 
correlated less strongly with FSH/LH ratio (at baseline) and TG (respectively, 
r=0.20 and r=0.19, p=0.05). Body weight positively correlated with glucose, insulin 
and HOMA-IR (respectively, r=0.23, r=0.44 and r=0.46, p=0.01), as well as TG 
(r=0.18, p=0.05), and HbA1c (r=0.16, p=0.05). Insulin and HOMA-IR positively 
correlated with HbA1c (r=0.25 and r=0.26, p=0.01), and TG level (r=0.36 and 
r=0.35, p=0.05) but negatively associated with HDL-C (respectively, r=-0.28 and 
r=-0.21, p=0.05). There was a positive correlation between FSH/LH ratio and T-
Chol (r=-0.17, p=0.05), and with LDL-C (r=-0.19, p=0.05). HbA1c inversly and 
significantly correlated with T-Chol (r=-0.21, p=0.01) and with LDL-C (r=-0.19, 
p=0.05). At 12 weeks, serum TSH correlated positively with body weight (r=0.21, 
p=0.01), BMI (r=0.22, p=0.01), insulin (r=0.24, p=0.01) and HOMA-IR (0.24, 
p=0.01). Serum TSH also correlated with serum progesterone at 4 weeks (r=0.18, 
p=0.05). Adiponectin level correlated positively with plasma glucose (r=0.32, 
p=0.05) and insulin (r=0.35, p=0.05), but no correlation was found between serum 
adiponectin and age, BMI and lipid paramters. LBP did  not correlate with any of 













5.2.2.2. Non-pregnant Women  
 
For the non-pregnant group (Table 14B), there was a weak but significant 
negative correlation between age and 12-week levels of glucose (r=-0.28, p=0.01) 
and insulin (r=-0.23, p=0.05) but positive correlation with LDL-C (r=0.22, p=0.05). 
Age and baseline ratio FSH/LH also correlated positively (r=0.32, p=0.05). 
Similarly to the pregnant group, weight and BMI were independently and 
significantly correlated with glucose (respectively, r=0.37 and r=0.42, p=0.01) and 
with insulin (respectively, r=0.36 and r=0.42, p=0.005); while negatively with 
LDL-C (r=-0.25, p=0.01 and r=-0.25, p=0.05). Oestrogen at 4 weeks positively 
correlated with TSH level at 12 weeks (r=0.28, p=0.01), while level of progesterone 
at 4 weeks correlated with final (12 weeks) HbA1c (r=0.19, p=0.05) and insulin 
level (r=0.27, p=0.01). Glucose and insulin positively correlated with T-Chol 
(respectively, r=0.38 and r=0.36, p=0.01) but negatively correlated with LDL-C 
levels (respectively, r=-0.32 and r=-0.29, p=0.01); insulin also negatively 
correlated with TSH value (r=-0.19, p=0.05). HOMA-IR positively associated with 
TG (r=0.93, p=0.01), T-Chol and LDL-C (respectively, r=0.35 and r=0.22, p=0.05), 
and negatively correlated with HDL-C (r=-0.23, p=0.05). As for pregnant women, 



















5.2.2.3. Correlation of Change in Glucose Level and in Other Parameters 
 
The association of change in glucose level from baseline to 12 weeks and 
compared to the other parameters (delta levels) for both groups is presented in Table 
15. In the pregnant group, the only two delta parameters values which were 
significantly associated with the change in glucose were HOMA-IR and isnulin. 
There was an inverse relationship between change in glucose level (12 weeks vs. 
baseline) and change in insulin level (B=-4.83; 95% CI=[-5.43,-4.24]; p<0.001); 
there was however a positive relationship between change in glucose level (12 
weeks vs. baseline) and change in HOMA-IR (B=8.99; 95% CI=[5.32,12.67]; 
p<0.001). Similar associations were observed in the non-pregnant group, with a 
negative relationship between change in glucose and insulin levels (B=-5.59; 95% 
CI=[-6.52,-4.67]; p<0.001) between measures at baseline and 12 weeks, and a 
positive relationship between change in glucose and HOMA-IR for the same time-
points (B=15.32; 95% CI=[6.34,24.29]; p<0.001). In addition, in the non-pregnant 
group, change in TSH between baseline and 12-week time-points negatively 
associated with change in glucose level. Overall, change in HOMA-IR level was 
shown to be the best predictor of change in glucose level at 12 weeks regardless of 

















Table 15: Difference in Glucose Level at Baseline vs. 12 Weeks and 
Compared to Changes in Other Anthropometrics, Metabolic and Endocrine 




Pregnant (n=158) Non-Pregnant (n=117) 
B 95% CI p value B 95% CI p value 
Weight -0.09 -0.34, 0.15 0.45 -0.19 -0.71, 0.33 0.47 
BMI 0.01 -0.70, 0.71 0.99 0.15 -0.67, 0.96 0.41 
Oestrogen_4 
weeks 
0.001 0.0001, 0.001 0.25 0.001 -0.001, 0.003 0.28 
Progesterone_4 
weeks 
-0.03 -0.07, 0.01 0.20 -0.002 -0.01, 0.004 0.53 
HbA1c 0.76 -1.17, 2.69 0.44 0.61 -1.77, 2.98 0.61 
Insulin -4.83 -5.43, -4.24 <0.001 -5.59 -6.52, -4.67 <0.001 
HOMA-IR 8.99 5.32, 12.67 <0.001 15.32 6.34, 24.29 <0.001 
T-Chol -0.002 -0.03, 0.29 0.92 -0.04 -0.11, 0.03 0.29 
TG 0.001 -0.01, 0.01 0.84 0.003 -0.02, 0.02 0.79 
LDL-C -0.02 -0.06, 0.02 0.26 0.02 -0.06, 0.09 0.64 
HDL-C 0.03 -0.03, 0.09 0.30 0.001 -0.10, 0.10 0.99 
TSH 0.09 -0.77, 0.95 0.84 -0.98 -1.98, 0.01 0.05 
ŦAdipo 0.002 -0.01, 0.01 0.69 -0.003 -0.01, 0.002 0.18 
ŦLBP 0.004 -0.02, 0.02 0.73 0.02 -0.02, 0.05 0.38 
Ŧn=73(42 pregnant, 31 non-pregnant); HbA1c: glycated haemoglobin; HOMA-IR: homeostatic 
model assessment of insulin resistance; T-Chol: total cholesterol; TG: triglycerides; LDL-C: low-
density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TSH: thyroid-

























Section 3: Results and Discussion 
 
 




















5.3. Early Predictors of Gestational Diabetes Mellitus  
5.3.1. Participants Characteristics 
 
The prevalence of GDM accounted for 22% in the pregnant group (n=158). 
In relation to the known anthropometric and medical predictors of GDM (including 
obesity, ethnicity, age, presence of PCOS and history of GDM), counting from the 
entire pregnant group: 23% had a BMI ≥30 kg/m2, 46% with PCOS, 5% with 
HbA1c ranging between 5.7–6.1% (39–42 mmol/mol) and 15% with a past history 
of GDM. Ethnicity of participants was multicultural: 53% Gulf nationals, 20% from 
Far East (South and East Asia), 15% Middle Eastern, 8% Europeans and 4% with 
African origins. Anthropometrics, metabolic and endocrine parameters of future 
GDM and non-GDM women are shown in Table 16; data are summarised as median 
(interquartile range). Compared to non-GDM pregnant women, at baseline 
participants who later developed GDM were 2 years older (p=0.03), 7kg heavier 
(p=0.01), with higher BMI (29.0 vs. 25.8 kg/m2; p<0.001) and presented with 
significant higher baseline levels of the following parameters: ratio FSH/LH by 
17% (1.20 vs. 1.0), HbA1c by 5% (5.50 vs 5.20% or the equivalent to 37 vs. 33 
mmol/mol), insulin by 33% (10.60 vs. 7.14 µIU/mL) and HOMA-IR by 23% (2.20 
vs. 1.70); with p<0.05 for all parameters. Women who later developed GDM also 
had higher baseline T-Chol (199.0 vs. 171.0 mg/dL or the equivalent to 5.17 vs. 
4.42 mmol/L; p=0.002) and LDL-C (123.0 vs. 104.8 mg/dL or the equivalent to 
3.18 vs. 2.71 mmol/L; p=0.003), and lower TG levels (74.0 vs. 76.0 mg/dL or the 
equivalent to 1.91 vs. 2.0 mmol/L; p=0.005) compared to non-GDM women. At 4 
weeks, pregnant women who later developed GDM had a significantly lower 4-
week glucose level compared to non-future GDM (83.5 vs. 85.30 mg/dL or the 
equivalent to 4.6 vs. 4.7 mmol/L; p=0.004), but significantly higher 4-week insulin 
(11.94 vs. 9.73 µIU/mL; p=0.02) and HOMA-IR values (2.40 vs. 2.10; p=0.01).  
At 12 weeks, compared to baseline, women with future GDM experienced 
significant body weight gain (delta change: 3.4kg, p=0.003), and reduction in 
fasting plasma glucose (88.38 to 80.0 mg/dL or the equivalent to 4.9 to 4.4 mmol/L; 
p=0.007) and in TSH levels (1.33 to 1.08 µIU/mL; p=0.05). In relation to 12-week 





TG (74.0 to 177.9 mg/dL, or the equivalent to 0.84 to 2.01 mmol/L), T-Chol (199.0 
to 211.4 mg/dL, or the equivalent to 5.15 to 5.47 mmol/L) and HDL-C (55.0 to 65.0 
mg/dL, or the equivalent to 1.42 to 1.68 mmol/L) levels compared to baseline, with 
all p<0.001. Comparable figures were found in non-GDM women at 12 weeks with 
significant increase in body weight (delta change: 1.5kg; p<0.001), reduction in 
fasting plasma glucose (85.3 to 81.0 mg/dL or the equivalent to 4.7 to 4.5 mmol/L; 
p<0.001), and in TSH levels (1.58 to 1.39 µIU/mL; p<0.001). Lipid profile was 
significantly increased at 12 weeks: TG (76.0 to 120.0 mg/dL or the equivalent to 
2.0 to 3.1 mmol/L), T-Chol (171.0 to 198.4 mg/dL or the equivalent to 4.42 to 5.13 
mmol/L) and HDL-C (57.0 to 63.0 mg/dL or the equivalent to 1.7 to 1.63 mmol/L), 
with all p<0.001. There were no significant changes in insulin, HOMA-IR, 
adiponectin and LBP levels at 12 weeks for both subsequent GDM and non-GDM 
groups compared to their baseline levels.     
In addition to the 14% higher preconception weight (75.9 vs. 65.0 kg; 
p=0.01), at 12 weeks, GDM women presented with greater weight gain (delta 
change: 3.4 vs. 1.5 kg), and higher levels of: insulin (11.33 vs. 7.57 µIU/mL; 
p=0.02) by 33%, TG (177.9 vs. 120.0 mg/dL or the equivalent to 2.01 vs. 1.35; 
p=0.003) by 33% and HOMA-IR (2.30 vs. 1.50; p=0.01) by 35% compared to non-
GDM group. The significant decrease in glucose and HbA1c levels have similarly 
occurred in the two groups (non-GDM and future GDM pregnant women) at 12 
weeks; values remain within normal range. Additionally, adiponectin and LBP 
levels did not differ between the two groups at 12 weeks. Amongst the parameters 
measured, the greatest difference between the two groups of pregnant women was 
a higher serum insulin level at baseline and at 12 weeks in pregnant women who 












5.3.2. Anthropometrics, Metabolic and Endocrine Correlations and 
Predictors of GDM  
Preconception and prenatal BMI (12-week) positively correlated with 
development of GDM (p=0.001) (Table 17). Interestingly, ethnicity, history of 
PCOS and of GDM did not associate with development of GDM (respectively, 
p=0.15, p=0.33 and p=0.88). Additionally, there was no relationship between 
number and gender of babies and GDM risk (p=0.80 and p=0.82).    
 
Table 17: Association of Women Characteristics and Pregnancy Outcomes 
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The anthropometric, metabolic and endocrine predictors of GDM are 
summarised in Table 18. Regression analyses revealed baseline FSH/LH ratio as a 
predictor of GDM (OR=2.05; 95% CI=[1.12,3.75]; p=0.02). Other predictors of 
GDM at 12 weeks include: HOMA-IR (OR=1.59; 95% CI=[1.16,2.17]; p=0.004), 
BMI (OR=1.16; 95% CI=[1.07,1.27]; p<0.001), age (OR=1.12; 95% 
CI=[1.01,1.23]; p=0.03) and insulin (OR=1.11; 95% CI=[1.03,1.18]; p=0.004). 
One unit increase in the ratio FSH/LH doubles the risk of development of GDM. 
Although preconception BMI associated with onset of GDM (OR=1.01; 95% 
CI=[0.73,1.39]; p=0.001), other baseline metabolic parameters (including lipid 
profile, glucose, HbA1c, LBP and adiponectin) did not associate with onset of 
GDM. After adjustment for maternal age and PCOS history, prenatal BMI (12-
weeks) was the only significant predictor of GDM (OR=1.11; 95% CI=[0.98,1.20]; 
p=0.03). Ratio FSH/LH was no longer a significant predictor of GDM, but 
approaching significance (p=0.08). Ethnicity and history of GDM were not adjusted 
for this analysis, given that they were shown to have a non-signifcant impact on 




















Table 18: Anthropometric and Metabolic Predictors of Gestational Diabetes 
Mellitus (as dependent variable) in Pregnant Women (n=158), adjusted for 
Age and PCOS using Binary Logistic Regression  
 
Variables 
Unajusted Analysis Adjusted Analysis 
OR 95% CI p value OR 95% CI p value 
Age 1.12 1.01, 1.23 0.03 1.14 0.99, 1.26 0.04 
PCOS 0.68 0.31, 1.48 0.33    
Ratio FSH/LH 2.05 1.12, 3.75 0.02 1.61 0.94, 2.78 0.08 
BMI_Baseline 1.01 0.73, 1.39 0.001    
BMI_F 1.16 1.07, 1.26 <0.001 1.11 0.98, 1.20 0.03 
HbA1c_F 1.77 0.64, 4.48 0.27    
Glucose_F 1.05 0.99, 1.11 0.11    
Insulin_F 1.11 1.03, 1.18 0.004 1.13 0.78, 1.70 0.53 
HOMA_F 1.59 1.16, 2.17 0.004 0.85 0.14, 4.88 0.85 
TG_F 1.01 0.99, 1.01 0.75    
T-Chol_F 1.01 0.99, 1.02 0.13    
Oestrogen_4weeks 1.00 1.00, 1.00 0.39    
Progesterone_4weeks 0.99 0.97, 1.01 0.34    
ŦAdiponectin_F 1.00 0.99, 1.00 0.71    
ŦLBP_F 0.99 0.99, 1.01 0.52    
Ŧn=75; PCOS: polycystic ovary syndrome; F: final (12 weeks); FSH: follicle-stimulating 
hormone; LH: luteinizing hormone; HbA1c: glycated haemoglobin A1c; HOMA-IR: homeostatic 
model assessment of insulin resistance; TG: triglycerides; T-Chol: total cholesterol; OR: odds 
ratio; C.I.: confidence interval 
 
The validity of documented cut-off levels of anthropometrics, metabolic 
and endocrine predictors of GDM is presented in Table 19. Prenatal BMI ≥35 kg/m2 
presented the highest impact factor on GDM with a six-fold (95% CI=[1.7,24.32]; 
p=0.002) increase in risk. Other predictors of GDM included 12-week levels of 
HbA1c ≥5.7% (39 mmol/mol) (OR=4.05; 95% CI=[0.95,16.93]; p=0.04), TG ≥137 
mg/dL (≥1.55 mmol/L) (OR=2.79; 95% CI=[1.28,6.07]; p=0.01), and Arab 





statistical significance in relation to 12-week TSH ≥2.5 µIU/mL and increased 
predisposition to GDM (OR=2.42; 95% CI=[0.92,6.37]; p=0.07). Age ≥35 years, 
HDL-C ≤85.5 mg/dL (≤2.20 mmol/L), log TG/HDL ≥0.099 and adiponectin ≤6.4 
µg/mL did not predict onset of GDM. 
 
Table 19: Levels of Anthropometrics, Metabolic and Endocrine Predictors 
of Gestational Diabetes Mellitus (GDM) at 12 Weeks using Evidence-based 







(n=124) OR 95% CI  p value 
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1.50 0.66, 3.43 0.34 







































2.42 0.92, 6.37 0.07 

































1.07 0.10, 11.53 0.96 
 Ŧn=75; p<0.05 vs. GDM, by Chi-square test; OR: odds ratio; C.I.: confidence interval; HbA1c: 
glycated haemoglobin A1c; TSH: thyroid-stimulating hormones; TG: triglycerides; HDL-C: 
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5.4. Pregnancy and Foetal Outcomes  
 
Delivery by caesarean section accounted for 65% in the pregnant group 
(n=158). Two participants were excluded from the final pregnant data (delivery 
point), since they experienced a miscarriage around mid-gestation. The present data 
account for n=156. In singleton, birth weight was 2.8 (0.58) kg; and in multiple 
pregnancy, 2.3 (0.51) kg for first baby and 2.2 (0.56) kg for the second.  
Multiple pregnancy (i.e twin pregnancies) positively correlated with 
delivery by caesarean section (p=0.002) (Table 20). Interestingly, presence of 
GDM did not associate with caesarean section (p=0.41).  
 
Table 20: Association of Pregnancy and Foetal Outcomes with Delivery by 






(n=103) p value 













 83.0 (44) 
17.0 (9) 
58.3 (60) 
 41.7 (43) 
0.002 
p<0.05 vs. caesarean section, by Chi-square test; GDM: gestational diabetes mellitus 
 
The assessment of maternal and foetal outcomes prediction of caesarean 
section is summarised in Table 21. Regression analyses revealed that maternal age, 
preconception BMI and BMI at 12 weeks of women did not predict delivering by 
caesarean section. In regards to foetal outcome, in singleton pregnancy, the weight 
of the baby did not predict a delivery by caesarean section but in multiple pregnancy 
only the weight of the first baby did (OR=0.03; 95% CI=[0.001,0.83]; p=0.038). 
There is a trend toward statistical significance in relation to weight of the second 
baby and its possibility in predicting a caesarean section (OR=19.96; 95% 
CI=[0.98,405.5]; p=0.051). When adjusting for 12-week BMI of pregnant women, 
the weight of first baby in twin pregnancies remained a significant predictor of 






Table 21: Maternal and Foetal Characteristics Predicting Delivery by 
Caesarean Section (as dependent variable) in Pregnant Women (n=158), 
adjusted for 12-week BMI using Binary Logistic Regression  
 
Variables 
Unajusted Analysis Adjusted Analysis 
OR 95% CI p value OR 95% CI p value 
Age 1.03 0.95, 1.11 0.49    
BMI_Baseline 1.06 0.98, 1.14 0.16    
BMI_12 weeks 1.06 0.99, 1.14 0.10    
Weight_Singelton 1.13 0.58, 2.21 0.73    
Weight_Twin1 0.03 0.001, 0.83 0.038 0.03 0.001, 0.91 0.044 
Weight_Twin2 19.96 0.98, 405.5 0.051 17.48 0.80, 381.9 0.07 
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6.1. IVF-related Maternal Characteristics and Outcomes  
 
Overall, the age of participants was within the optimal range for 
reproductive age (<35 years) and also favourable for IVF and pregnancy 
outcomes6–8. Advanced age, known as one of the important factors of female 
infertility, did not affect IVF pregnancy rate. A subgroup of participants was older, 
partly explained perhaps that they were seeking IVF therapy for gender selection. 
Despite the high rate of obesity and PCOS in the UAE27, percentages of participants 
with a preconception (or baseline) BMI in the obese range and/or history of PCOS 
were not as high as expected. The difference may be explained by the ethnic 
diversity in the UAE205 and hence of participants in this study. Overall, participants’ 
preconception BMI was within the overweight range (BMI 25–29 kg/m2) and 
remained so when measured at 12 weeks. Even though weight gain was statistically 
significant during the first trimester of pregnancy, it did not exceed the 
recommended weight-gain of 0.5–2.0kg251. At baseline, 17% of women had pre-
diabetes (HbA1c 5.7–6.4% or the equivalent to 39–47 mmol/mol)199, 4% presented 
with high insulin level (>24 µIU/mL)252 and 31% were insulin resistant based on 
HOMA-IR >2.5218. Lipid profile and TSH levels were within normal range at 
preconception stage179,180,253.  
 
6.2. IVF-related Foetal Outcomes  
 
Controversies have not yet been resolved as to whether adverse foetal and 
neonatal outcomes are more prevalent with IVF-conceived pregnancy56,59,71,72, due 
to a lack of relevant published data after the first trimester; especially that in some 
cases pregnant women may be administered exogenous hormones (mainly 
progesterone) until late gestation. Longitudinal prospective studies on IVF-
conceived children will be helpful to assess their development and predisposition 







6.3. Effects of IVF Therapy on Metabolic, Inflammation and 
Endocrine Systems 
6.3.1. Metabolic Profile   
 
IVF hormonal therapy raised glucose and insulin levels, and reduced insulin 
sensitivity (increased HOMA-IR), evidenced in failed IVF cycle at 4 and 12 weeks 
measurements. These metabolic excursions likely reflect changes in serum 
progesterone levels. In compliance with the theory, a negative correlation was 
shown  between change in glucose level and that of insulin between baseline and 
12-weeks, and positive correlation between plasma glucose and HOMA-IR. In 
addition, change in HOMA-IR level predicted best the change in plasma glucose 
level between baseline and 12 weeks regardless of pregnancy status. A similar 
relationship between  insulin sensitivity and glucose intolerance was reported with 
long-term use of oral contraceptives99–101. Oestrogen therapy at a dose of 1.25 
mg/day for a three year period was previously suggested to be associated with a 
25% decrease in insulin sensitivity102. In this study, a reduction of 10% in insulin 
sensitivity (based on HOMA-IR) was found with 6 mg/day of exogenous oestrogen. 
It is possible that longer duration of hormonal therapies may have a greater impact 
on glucose and insulin homeostasis than a high hormonal dose for a shorter 
duration.            
 During early gestation, dogma states that glucose homeostasis (including 
glucose and insulin levels, and insulin sensitivity) remains similar to that of non-
pregnant women79–81. However, some studies have shown a drop in plasma glucose 
level during early pregnancy254 and/or 20% increase in insulin synthesis to maintain 
euglycaemic levels81,255. The effect of IVF hormones on glucose homeostasis was 
down-regulated by pregnancy, whereby, no change in insulin level and sensitivity 
(HOMA-IR) were observed, while glucose level was reduced (still remained within 
normal range). The drop in plasma glucose during pregnancy has different 
explanations. In response to the increased foetoplacental energy requirements in 
early pregnancy, a physiological adaptation triggers focus on carbohydrates (i.e. 
glucose) instead of lipids as a source of energy87,88,256. The drop in glucose level in 





volume increases254. Later in pregnancy, increased glucose level is related to 
impairment in glucose tolerance, which is in accordance with excessive increase in 
insulin level and reduced insulin sensitivity84,257. Controversies exist in relation to 
the change of HbA1c in pregnancy, with most studies reporting a decrease in the 
first trimester258, concordant with the findings from this IVF study. The 
diabetogenic state from increased insulin resistance and hyperinsulinemia usually 
manifests during mid-pregnancy79–81. Accordingly, such changes did not occur by 
12 weeks of gestation. The findings from this study suggest that IVF-related 
hormonal therapy does not hasten the diabetogenic effect of pregnancy during the 
first trimester. However, when planning repeated cycles of IVF therapy (e.g. egg 
banking cycles and post-failed IVF cycles), it is important to monitor plasma 
glucose and serum insulin levels.   
6.3.1.1. Glucose and Insulin Homeostasis  
 
At week 2 of IVF therapy, the effect of exogenous FSH and LH on glucose 
and insulin were assessed compared to baseline levels; week 2 to 4 represented the 
effect of oestrogen and progesterone, and additional pregnancy effect after week 4. 
The significant decrease in glucose level at week 2 in both pregnant and non-
pregnant groups may have different possible explanations: 1) impact of exogenous 
FSH and LH hormones, 2) longer than 10 hours fast of participants, 3) participants 
were instructed by the IVF educator at the clinic to reduce carbohydrates intake (as 
proven to be beneficial for the treatment) and they ended up eating less the night 
before the procedure. The role of FSH on glucose metabolism remains incompletely 
understood. A study by Wang et al. reported lower FSH levels in prediabetes and 
diabetes in post-menopausal women compared to controls, associated with 
adiposity and insulin resistance199,259. This promotes the notion of FSH as a novel 
biomarker of GDM risk. The association between serum FSH and GDM lacks 
verification in this IVF study due to adjustments of the doses of IVF hormones 
(FSH and LH) according to baseline levels. Additionally, FSH level was not 
measured at 2 weeks to verify if there was any correlation between FSH level and 





hormones did not seem to have affected insulin level and insulin sensitivity. More 
studies are required to clarify the effect of FSH and LH hormones on glucose 
homeostasis. GnRH hormone (administered a few days before OPU procedure) did 
not influence glucose or insulin levels260, this may have been better confirmed if 
glucose and insulin levels were also measured just before the GnRH injection was 
initiated.  
At week 2 of IVF therapy, exogenous oestrogen and progesterone were 
initiated. Measurement at week 4 marks not only the difference in pregnancy status 
but also distinguishes pattern of change in glucose and insulin levels between the 
two groups. Compared to week 2, exogenous reproductive hormones (oestrogen 
and progesterone) increased glucose and insulin levels, and insulin resistance 
(HOMA-IR) in both pregnant and non-pregnant groups, with a much greater 
increase in insulin and insulin resistance in the non-pregnant women at 4 weeks. 
The lower increments observed in the pregnant group may be due to pregnancy 
effect. The effect of IVF hormones on raising glucose level at 12 weeks was down-
regulated by pregnancy, while insulin level and sensitivity were fully reverted to 
baseline levels. The increased in glucose level post-failed IVF (at 12 weeks) may 
have different possible explanations. As mentioned earlier, non-pregnant women 
presented with a significant weight gain (and possibly of adiposity) at 12 weeks, 
which may have affected glucose level. In addition, post-failed IVF may elucidate 
poor mental well-being, with a risk of depression and anxiety261–263. Mental distress 
is associated with elevated plasma cortisol level and in which is thought to affect 
glucose metabolism264,265. Mental stress of participants was not measured and 
hence this remains a speculative explanation. 
6.3.2. Inflammation and Gut Microflora  
6.3.2.1. Gut Microflora  
 
 Female reproductive hormones (oestrogen and progesterone) stimulate 
synthesis of inflammatory markers110. A similar response is expected to occur with 
IVF hormonal therapy. Gut dysbiosis has been previously linked to insufficient or 





thought to affect LPS signalling and may trigger an inflammatory response149,156. 
Interestingly, the exposure to IVF hormonal therapy did not provoke any change in 
LBP level at 12 weeks for both groups of women. Consequently, it can be 
speculated that no related impairment in LPS level or in gut microflora occurred. 
One possible explanation of unchanging LBP levels relates to diet, an important 
modulator of intestinal microbiota diversity and richness132. Women undergoing 
IVF therapy might have been more conscious in their food choices by avoiding high 
fat/energy dense diets. Unlike a high fibre diet, high fat/calories diet may induce 
micro-inflammation and increased endotoxin to appear in the circulation, resulting 
from changes in gut permeability and microflora diversity114,117. Physiological and 
hormonal changes during pregnancy also mediate an inflammatory response109. In 
the presented IVF study, LBP level did not correlate with any endocrine and 
metabolic parameters, indicating that IVF-conceived pregnancy did not hasten the 
inflammatory-related effect of pregnancy.  
Gut microflora composition has been linked to preconception BMI and 
gestational weight gain in pregnancy266, but no such link was detected at 12 weeks 
of pregnancy. In addition, obesity-related gut microflora disturbances may result 
from gestational inflammation, increased body fat and decreased insulin sensitivity 
during pregnancy152. This physiological change was not observed in this IVF study 
(with unchanged HOMA-IR level), possibly because parameters were tested too 
early in pregnancy to see any effect. Therefore, in early gestation, gut microflora 
remains intact and uninfluenced by hormonal changes of glucose and lipids 
homeostasis, and thyroid profile.    
6.3.2.2. Adiponectin Level 
 Adiponectin, a useful marker of inflammation and insulin sensitivity, is 
thought to gradually decrease during pregnancy, secondary to hormonal fluctuation 
or in response to stress113,116. Low maternal adiponectin level during early 
pregnancy predicted an increased risk of GDM113. At 12 weeks of IVF-conceived 
pregnancy, adiponectin level was identical to baseline and to levels in the non-
pregnant group. Surprisingly, adiponectin level did not correlate with insulin or 





however in this IVF study a positive correlation was found between adiponectin 
and glucose levels at 12 weeks and both parameters can be reduced in early 
pregnancy. In relation to adiponectin anti-inflammatory properties and lipid 
metabolism113,228, lipid parameters were increased at 12 weeks (TG, T-Chol, and 
HDL-C) regardless of pregnancy status, but likely not adiponectin related since no 
positive correlation was detected between adiponectin or any of the lipid 
components. Adiponectin impairs LPS activation of the inflammatory cascade and 
insulin resistance156. However, there was no correlation between LBP and 
adiponectin, which may have also expectedly resulted in no association with LPS 
in this presented study. Regardless of pregnancy, exposure to IVF hormonal therapy 
did not mediate an inflammatory response, consistent with unchanging adiponectin 
levels. Furthermore, IVF-conceived pregnancy within the first trimester does not 
seem to be more predisposed to an inflammatory environment compared to a 
spontaneous pregnancy.   
6.3.2.3. Lipid Profile 
 The interplay between inflammation and lipid metabolism is well 
documented, and the two play an important role in the pathophysiology of 
metabolic conditions, such as insulin resistance. T-Chol and lipoprotein may trigger 
the inflammatory system, and inter-relatedly, pro-inflammatory cytokines may 
impair lipid metabolism267. Insulin resistance and hyperinsulinemia are often 
featured with obesity and/or PCOS and are associated with hyperlipidemia140. 
Despite the high prevalence of PCOS and obesity in the participants of the 
presented IVF study, lipid profile was normal at baseline and remained so at 12 
weeks. However, there was an excursion of lipid components between baseline and 
12 weeks. Deterioration in insulin sensitivity following IVF hormones positively 
associated with changes in TG, T-Chol and LDL-C levels, but negatively with 
HDL-C. Similarly to oral contraceptives101,141–143, IVF hormones augmented lipid 
parameters, but values remained within normal range possibly due to the short 
duration of the treatment.   
 Metabolic and hormonal changes of pregnancy impose changes on lipid 





yet conclusive. Lipid metabolism plays a role in pregnancy and ensures sufficient 
nutrients for the foetus. While TG serves as energy storage, T-Chol is implicated in 
normal foetal development. During early gestation, an anabolic phase 
predominates, whereby lipid synthesis and maternal fat stores are increased to 
prepare for future higher energy needs of both pregnancy and foetus later in 
pregnancy (characterised as a catabolic phase); this effect is assisted by increased 
insulin sensitivity136,256. Mixed reports exist regarding changes in lipid metabolism 
during pregnancy. Pregnancy-related hyperlipidemia usually manifests in mid-
gestation and onwards with higher TG, T-Chol, LDL-C and HDL-C levels134. At 
12 weeks of IVF-conceived pregnancy, lipid profile complied with normal changes 
of pregnancy and similar to previous studies, showed an increase in TG, T-Chol 
and HDL-C levels134,135,138,139. In the present study, increased lipid profile 
combined with decreased glucose level (described earlier) confirm the suggested 
notion of enhanced fat accretion and use of fat as a source energy by the mother in 
early pregnancy, to ensure sufficient glucose supply to the foetus88,256. The 
attributable effect of IVF hormones on lipids in pregnancy cannot be determined 
because of disparities in duration of IVF hormonal therapy exist between the two 
groups (4 weeks for non-pregnant vs. until 12 weeks of pregnancy). Furthermore, 
a cumulative effect would have been identified if lipid parameters exceeded the 
reference ranges in pregnancy253. Finally, inclusion of a well-matched spontaneous-
pregnant group would have allowed determining the magnitude of change in lipid 
profile as an effect of pregnancy alone. Increased gestational hormones, mainly 
progesterone, are implicated in increased fat storage136; however, no correlation 
was found between progesterone and TG levels.  
 As previously mentioned, hyperoestrogenemia stimulates hepatic synthesis 
of lipids138, and possibly influences changes in TG, T-Chol and HDL-C levels at 
12 weeks. In accordance with the effect of oral contraceptives on lipids88,101,141–143, 
increased TG level was the principal observed change for both pregnant and non-
pregnant women following IVF therapy. Changes in TG level are thought to be 
oestrogen-dose-related142; however, there was no correlation found between TG 





hormones were measured at 12 weeks. The same reasoning can also be extended to 
the potential correlation that would have been seen at 12 weeks between oestrogen 
and T-Chol levels. The increase in TG level may impair insulin sensitivity and vice 
versa101. Hypertriglyceridemia may result from increased body fat and reduced 
lipolytic activity134,139, evidenced in the presented IVF study by a positive 
correlation between weight and TG level at 12 weeks. Reduced lipolysis may occur 
as a result of impaired insulin sensitivity, with reduced ability of insulin to suppress 
lipolysis116. The significant positive correlation between HOMA-IR (as a marker 
of insulin resistance) and insulin level, independently with TG level was shown in 
both groups. However, although hypertriglyceridemia was not observed during the 
first trimester in participants of this study, there was also a positive correlation 
between TG level and BMI at 12 weeks of pregnancy, which is expected to be 
intensified with increased adiposity later in pregnancy. Taken together, it can be 
speculated that IVF hormonal-related deterioration in insulin sensitivity observed 
with failed IVF may have reduced lipid oxidation113. Therefore, caution should be 
exercised when planning several consecutive IVF cycles or when extending the 
duration of the therapy (as in the case of poorly responding women). On another 
note, the absence of change in LDL-C level with IVF hormones regardless of 
pregnancy status does not explain the known hormonal association with increased 
risk of coronary heart diseases with oral contraceptives19.  
6.3.3. Endocrine Profile 
Participants had normal TSH level at baseline (0.4–4.0 µIU/mL), which 
eliminated the possible effect of TSH on impairing IVF and pregnancy 
outcome176,177. The positive correlation between oestrogen and TSH levels (at 12 
weeks) was only observed in negative pregnancy, confirming that oestrogen 
therapy of IVF has an effect on TSH; this effect was masked in clinically confirmed 
pregnancy159,164. In addition, an inverse association was found between the change 
in glucose level and that of TSH at 12 weeks for non-pregnant women, which 
endorses the well-known relation between thyroid hormone, insulin secretion and 
glucose homeostasis192,249. However, while IVF hormonal therapy induced increase 





(at 12 weeks) with absence of clinical pregnancy. Taken together two possible 
explanations may be proposed. Firstly, IVF hormones were stopped at 4 weeks and 
oestrogen therapy has already been cleared out from the body, or that duration of 
IVF hormones administration was too short to induce changes in TSH level. 
Conversely, the effect of oestrogen therapy on raising TSH level would have 
possibly been seen at 4 weeks of treatment, but it was not measured at that time. In 
pregnancy, TSH level decreased at 12 weeks, and complied with previous 
investigators reporting 20–50% suppression due to sharp increase in hCG 
concentrations174. Level of TSH complied with the American Thyroid Association 
recommendation of TSH range of 0.1–2.5 µIU/mL in the first trimester171. In early 
gestation, TSH measurement is not a good indicator for diagnosing thyroid 
dysfunction, and instead T4 and T3 hormones should be tested for a better 
assessment of thyroid function; TSH level is more reflective of thyroid status later 
in gestation (>16 weeks)171. There was a positive correlation, albeit weak, between 
progesterone and TSH levels. This observation is explained by the normal 
metabolic-related suppression of TSH throughout pregnancy, with the lower TSH 
level happening in the first trimester169,170, and expected to increase with increased 
progesterone level. Prenatal weight and BMI were also found to be positively 
correlated with TSH level, suggesting that abnormal maternal weight gain may 
predispose the most to the change in thyroid level during pregnancy, and 
emphasises the well-known correlation between thyroid function and obesity268. 
Correspondingly, an association between thyroid hormones and adiposity-related 
cytokines (e.g. adiponectin) was proposed in the literature, but findings remain 
inconclusive268. Additionally, insulin and TSH levels were positively correlated at 
12 weeks of pregnancy, and this is explained by the interrelation between the two 
parameters, whereby, both hypo- and hyperthyroidism impair insulin sensitivity. 
Conversely, hyperinsulinemia may block the conversion of T4 to its active form 
T3, and therefore impairs thyroid profile175,176. Consequently, a longer exposure to 
IVF therapy during pregnancy would have probably evidenced an increase in 
insulin level and resulted in such observations. IVF-conceived pregnancy appears 





attention should be geared towards thyroid levels post-failed IVF with repeated 
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6.4. Early Predictors of Gestational Diabetes Mellitus  
6.4.1. Characteristics of Women with GDM   
 
Unrecognised diabetes during pregnancy is associated with increased 
adverse outcomes and risks for the mother, foetus and neonate. IVF-conceived 
pregnancy has previously been considered a ‘high-risk’ intervention with increased 
risk for maternal and obstetric complications, such as GDM6,52,59–62. The prevalence 
of GDM in this study was expected to be higher given the “high-risk” intervention 
and the fact that participants presented with strong GDM predisposing factors: 
obesity (BMI >30 kg/m2), advanced age (>35 years), high incidence of PCOS, 
predisposed ethnicities and/or communities (South and East Asia, Gulf and Middle 
East) and exaggerated maternal weight gain55,88,180,189–191,193,201,269. GDM rate from 
this study was almost comparable with the latest national statistics on spontaneous 
pregnancies, whereby one in every three pregnant women in the UAE develops 
GDM187,188. Accordingly, this may reject considering IVF-conceived pregnancy as 
a powerful risk factor for GDM.     
 Women who developed GDM were older (still below the high-risk age 
group, i.e. <35 years) and more overweight (closer to obesity range) compared to 
those who did not develop GDM. They also presented at baseline higher levels (still 
within normal reference) of the well-known glucose, insulin and lipids-related 
markers of GDM196,200: HbA1c, insulin, HOMA-IR, T-Chol and TG. In addition, 
baseline FSH/LH ratio was also significantly higher for this group, which hints the 
possibility of being an early predictor and/or risk factor of GDM; the mechanism 
remains unclear. Ratio of FSH/LH measurement during the first trimester should 
be further investigated in predicting onset of GDM.      
 At 12 weeks, pregnant women who went on to develop GDM experienced 
more weight gain (from baseline) compared to non-GDM women, and this 
exceeded the recommended weight gain of less than 2.0 kg during the first 
trimester251. Initially, plasma glucose of future GDM was not different from non-
GDM women levels and remained so at 12 weeks (taking into account the 
significant similar drop in glucose level in both groups of women from baseline to 





GDM. Hence, another important point for early metabolic changes in pregnancy is 
related to maintaining normoglycaemia in the first trimester, and only later in the 
second trimester does GDM develop. In relation to screening for early predictors 
of GDM, neither glucose nor HOMA-IR levels at 12 weeks revealed to be good 
predictors in this study. Findings from this study also supports that assessment for 
GDM with OGTT later in the second trimester may be more accurate rather than in 
the first trimester.       
 Compared to the other aforementioned predictors of GDM at baseline, TG 
level was the only one to increase significantly at 12 weeks (and significantly differ 
from non-GDM 12-week levels), which in turn highlights its importance as a strong 
risk factor of GDM. Baseline levels of adiponectin and LBP did not predict GDM 
risk. Furthermore, no change in levels of these parameters occurred at 12 weeks in 
either group. Insulin level remained higher at 12 weeks in future GDM pregnant 
women, but the level was not different from baseline. Insulin should hence be 
considered in assessment of GDM risk in addition to the well-recognised strong 
predictors including TG level, preconception and prenatal BMI, as well as weight 
gain during pregnancy.  
6.4.2. Anthropometric and Medical Predictors  
 
Numerous studies have emphasised the association between preconception 
BMI, gestational weight gain and GDM risk201,270,271. The presented study has 
evidenced that increased GDM risk was strongly and equally associated with both 
pregravid and prenatal obesity. However, when adjusting for age and PCOS history, 
only BMI at 12 weeks was a significant determinant of GDM risk. Hence, the 
higher the BMI at the first trimester (i.e. 12 weeks), the greater the risk of GDM in 
mid-gestation, with four-fold increase for BMI ≥30 kg/m2 and six-fold for a BMI 
≥35 kg/m2. This finding complies with previous studies’ reporting that being in the 
overweight (BMI: 25–29.5 kg/m2) or obesity category (BMI >30 kg/m2) is the most 
important predisposing factor for GDM272. Advanced age, essentially considered a 
powerful risk to adverse obstetric outcomes in pregnancy, was also effectively an 





years was not a significant age-predictor level for higher GDM risk. Previous 
history of GDM and PCOS did not predict the onset of GDM in participants of this 
study.           
 The number of pregnant women with a history of GDM was small given 
that a large proportion of participants referred for primary infertility, and this may 
have affected the impact of GDM history. In addition, ethnicity was not associated 
with increased GDM risk when classifying participants into seven groups (Middle 
Eastern, Gulf, African origins, South Asia, East Asia, Europeans and North 
Americans). However, when categorizing participants into two groups (Arab vs. 
non-Arabs), the Arab ethnic group was more predisposed to develop GDM. It is in 
fact well evidenced that the Arab communities (including the Gulf, Levant and 
Middle East) are more at risk of GDM192,249.  
Pregnancy outcome and foetus characteristics did not serve as early markers 
of GDM. Multiple pregnancy has long been considered as a predisposing risk for 
complications and adverse medical outcomes (such as GDM)41,53. There was no 
detected association between gender and number of babies with GDM risk in IVF-
conceived pregnancy. A well-matched group of spontaneously-conceived 
pregnancy, including those with multiple pregnancy would have helped in the 
assessment of the impact of IVF-conceived pregnancy on obstetric outcomes. 
 The well-studied glucose and lipid markers of GDM have poorly served this 
purpose in this IVF study (i.e. glucose, HbA1c and TG levels). Baseline ratio of 
FSH/LH was the best predictor of GDM risk followed by levels of the following in 
decreasing order at 12 weeks: HOMA-IR, prenatal BMI, age and insulin level. 
However, when adjusting for age and history of PCOS, the FSH/LH ratio no longer 
showed a significant early predictor of GDM risk, and prenatal BMI was the 
strongest predictor. This may be caused by the higher prevalence of PCOS, 
advanced age and/or poor ovarian reserve in the population of this presented study; 
these conditions affect FSH level. PCOS women have lower FSH level secondary 
to reproductive hormone imbalance, and not related to any kind of glucose 
homeostasis disparities273. Elevated FSH in older women indicates poor ovarian 





FSH/LH ratio in participants of this IVF study. Lower FSH level was previously 
reported in prediabetes and diabetes post-menopausal women199,259; however, FSH 
level at 12 weeks of pregnancy was not measured to assess the possibility of 
considering FSH as an additional predictor for GDM. Overall, in addition to the 
known risk factors of GDM, there should be an emphasis on preconception FSH/LH 
ratio and BMI in clinical practice as early high-risk markers, and close surveillance 
of early gestational gain of weight should be a focus as a predictor for onset of 
GDM.       
Prevention trials have not yet confirmed optimal lifestyle intervention and 
macronutrients distribution to prevent the onset of GDM274–276, and neither 
guarantee that gestational-related adiposity can be prevented by one specific 
intervention277. Preconception care seems to be an ideal window of opportunity to 
prepare women who are planning to get pregnant. In line with this, the American 
Diabetes Association and American College of Obstetrics and Gynaecologists 
recommend management at the preconception stage, during which modifiable risk 
factors like high BMI can be improved278. Preconception weight loss cannot be 
emphasised enough as a mean to improve fertility and IVF success rate, as well as 
reduce risks for both mother and foetus277. A BMI <35 kg/m2 is recommended 
before commencing any fertility treatment21–24, given that pregnancy is associated 
with weight and fat gain, which in turn will be more problematic if preconception 
BMI exceeds the normal range. In the presented IVF study, high risk of GDM was 
experienced at a lower BMI cut-off (≥30 kg/m2), which hence suggests aiming for 
a lower preconception BMI and enforces the NICE guidelines25 for a BMI <29 
kg/m2 before commencing any ART treatment. Several studies have affirmed that 
as little as a 5% and ideally 10% weight loss were sufficient to improve 
reproductive hormonal profile and menstrual cyclicity, as well as insulin sensitivity 
and risk of GDM, in obese women with and without PCOS15,279,280. A study by 
Stubert et al. reported that 10% reduction in BMI associated with about 10% 
reduction in risk of preeclampsia and GDM277. Healthy lifestyle intervention, 
comprising a balanced dietary plan and regular physical activity, may promote 10 





of 38 kg/m2 in advanced age recommended by HAAD (UAE) may in fact be worth 
delaying by a reasonable period to achieve some weight loss; this will improve IVF 
success rate (including quality of eggs) and pregnancy outcome.  
6.4.3. Glucose Homeostasis Markers  
 
During pregnancy, insulin maintains normoglycaemia. Insulin secretion 
increases in response to elevated plasma glucose level and to counteract reduction 
in insulin sensitivity, the latter corresponding to pre-GDM situation207. In this 
study, a significant reduction in plasma glucose level at the first trimester of IVF-
conceived pregnancy (at 12 weeks) was found with no change in insulin level, 
which the latter may be related to increased metabolic demand at this time for 
glucose. Hence, glucose level was not reliable enough to predict GDM risk in this 
study. The decrease in glucose level can be related to different factors, including 
longer than 10 hours fast, poor nutritional intake secondary to pregnancy-related 
nausea and more importantly, it can result from a physiological adaptation where 
the body uses mainly glucose as a source of energy to the foetus87,88. The use of 
HbA1c (average of glucose for three months) for predicting, diagnosing and 
managing GDM remains inconclusive200,255,281. Additionally, HbA1c is thought to 
be a weak surrogate of insulin sensitivity and secretion204. Level of HbA1c can be 
influenced by different factors: anaemia, physiological hydraemia, gastrointestinal 
disorder (such as hyperemesis gravidarum) and dietary intake204,255. Unfortunately, 
information in relation to participants’ dietary intake and gastrointestinal disorders 
were not collected. Given that HbA1c was also significantly lower at 12 weeks 
(unlike with the presence of pre-GDM), may reject its possibility as an early marker 
for GDM in this IVF study. When narrowed down, an HbA1c ≥5.7%  at 12 weeks 
associated with a four-fold higher risk of develoving GDM. Altogether, even 
though the literature does not support relying on HbA1c to predict GDM, it can be 
used to identify those at high risk of adverse pregnancy outcomes and who may 
benefit from early intervention, especially if presenting with HbA1c above 5.7% at 
<20 weeks of gestation200,202,203,206.     





risk of GDM, which is often the case for women with PCOS11,12. In addition, the 
risk of GDM was documented in the literature to be higher with increased HOMA-
IR at the second trimester282. This observation is compatible with findings from the 
presented IVF study, whereby even with unchanged levels in insulin and HOMA-
IR at 12 weeks, these parameters successfully predicted GDM risk at an even earlier 
stage. However, when adjusting for history of PCOS, HOMA-IR and insulin level 
were no longer significant valid predictors of GDM. This may suggest that early 
gestation insulin and HOMA-IR levels of participants may be related to their PCOS 
condition rather than a pregnancy effect. Additionally, decreased insulin sensitivity 
(based on HOMA-IR) positively correlated with significant maternal weight gain 
and BMI during the first trimester; which in turn emphasises further the well-known 
role of obesity in the aetiology of insulin resistance and GDM256.  
 The OGTT test for GDM is conducted around 24–28 weeks of 
gestation195,196,198, whereby, many changes in glucose homeostasis have already 
happened with possible sequelae on mother and foetus. Measuring routinely insulin 
parameters in the first trimester may predict GDM and protect mother and foetus 
from related adverse events. 
6.4.4. Other Endocrine and Metabolic Markers  
 
This presented IVF study corroborates previous findings in relation to 
thyroid-mediated regulation of glucose metabolism and that thyroid impairment 
may be a risk factor for the development of GDM221. Low TSH level decreases 
insulin sensitivity; correspondingly in the presented study, TSH level inversely 
correlated with (unchanged) levels of insulin and HOMA-IR at 12 weeks. Change 
in glucose level did not however associate with change in TSH suggesting that the 
change in glucose homeostasis was more likely a physiological adaptation, rather 
than related to thyroid status. It should be noted that reduced TSH level remained 
within the normal range180; and this might have affected power to show any 
association between TSH and glucose. In contrast to other studies’ findings222, only 
few participants (n=6) experienced a low TSH level (<0.04 µIU/mL) at 12 weeks, 





make meaningful conclusions, and it would have been interesting to measure other 
thyroid-related hormones (T3 and T4) to confirm diagnosis of thyroid impairment. 
In sum, TSH level at 12 weeks poorly predicted GDM risk, especially when the 
change in level remains in the normal range. In relation to the American Thyroid 
Association TSH cut-off of <2.5 µIU/mL associated with lower maternal adverse 
outcomes170,181,182, exceeding this level during the first trimester doubled GDM risk 
in the pregnant group in this presented study, with a trend toward statistical 
significance.  
In relation to lipid profile and risk of GDM, unlike insulin the observed 
decrease in glucose level at 12 weeks did not associate with change in lipids (TG, 
T-Chol, LDL-C and HDL-C). Insulin regulates lipid metabolism, and triggers 
hepatic and fat tissue TG synthesis218. Even with unchanged insulin homeostasis, 
there was a positive correlation between levels of insulin and TG and negative with 
HDL-C at 12 weeks. Enquobahrie et al. highlighted the positive association 
between elevated TG (>137 mg/dL or the equivalent to 1.55 mmol/L) and GDM 
risk with 3.5-fold increased risk even after adjusting for pre-pregnancy adiposity, 
and found that each 20 mg/dL increase in TG promoted a 10% increase in GDM 
risk223. Independently of obesity, TG ≥140 mg/dL (1.58 mmol/L) was characterised 
as an important risk factor for GDM, with a 1.8-fold higher GDM risk in lean and 
2.7-fold in the obese group225. Contrary to other studies, the potential predisposition 
to GDM when considering median TG level was not observed in the presented IVF 
study223–225, possibly because levels of lipid parameters remained within normal 
ranges at 12 weeks despite their significant increase from baseline. However, with 
TG ≥137 mg/dL, pregnant women from this study were 2.8 times more predisposed 
to GDM, likely related to the effect of insulin. The study by Li et al. reported 
increased serum TG, T-Chol, and LDL-C, and decreased HDL-C concentrations in 
GDM women, compared to control groups; pointing out the possibility of HDL-C 
as a risk factor of GDM225. Abell et al. expanded on this finding noting that GDM 
women presented with lower HDL-C concentration (60 mg/dL) during the first 
trimester of their pregnancy, and HDL-C ≥85.5 mg/dL reduced GDM risk by 50% 





excluding its possibility in predicting GDM. Additionally, 12-week HDL-C ≥85.5 
mg/dL did not protect from GDM risk for participants in the presented IVF study.
 The logarithm of TG/HDL-C ratio, commonly used as an atherogenic 
marker ( Log TG/HDL-C >0.099) and to identify pregnant women with higher risk 
of GDM before 24 weeks of gestation226. When tested on participants in the study, 
log TG/HDL of more than 0.099 did not predict a higher risk of GDM. Early 
pregnancy lipids were hence not sufficient in predicting GDM, especially given that 
concentrations remained within the guideline ranges.    
 Future studies assessing GDM predisposition from lipid precursor 
hormones, which are associated with obesity, PCOS and reduced insulin sensitivity 
are needed. Vitamin D, derived from cholesterol and commonly deficient in 
pregnancy, affects glycaemic control and is thought to have a strong implication in 
GDM pathophysiology119,283; the related mechanism is worth further investigation. 
The Gulf region (including UAE) and certain ethnicities are more prone to vitamin 
D deficiency (e.g. South Asia, the Middle East and Africa), which characterises a 
large portion of the participants in this study284–286. Additionally, given the 
association of vitamin B 12 with insulin resistance and obesity, it would be 
interesting to explore its role in GDM. Vitamin B 12 level was shown to be 
inversely associated with fasting glucose level and negatively with BMI in early 
pregnancy287; highlighting its potential role as a novel biomarker of GDM.  
6.4.5. Inflammatory Markers  
 
Low grade inflammation is associated with increased risk of insulin 
resistance and T2DM, while limited data is available in relation to inflammatory 
predictors of GDM; a condition which is pathophysiologically similar to T2DM288. 
Increased inflammatory profile in the first trimester has been previously reported 
in women who later develop GDM289. Adiponectin and LBP levels were measured 
to assess the inflammatory status of pregnancy and related predisposition to GDM. 
Strong evidence has reported lower adiponectin levels in obesity, pregnancy and 
GDM; its role in the pathophysiology of GDM crosses different mechanisms146. 





adiponectin at 12 weeks, but the decrease in glucose level was not paired with any 
change in adiponectin. Consequently, the observed change in glucose level may not 
be related to the anti-glycaemic properties of adiponectin and rather a pregnancy 
effect116. Additionally, unchanged levels of insulin and adiponectin levels confirm 
previous findings that changes mainly occur after the second trimester207.  
As previously mentioned, GDM is characterised by inflammation and 
insulin resistance, and early signs of inflammation precedes the condition116. Given 
that adiponectin level did not differ between women who later developed GDM and 
non-GDM group, this suggests that either IVF-conceived pregnancy does not 
promote an inflammatory response in pregnancy, or that it was too early to see any 
inflammatory response within the first trimester. In line with this finding, 
hypoadiponectinemia (adiponectin level <6.4 ug/mL) at 12 weeks of pregnancy did 
not associate with increased risk of developing GDM in this study113,227. Measuring 
adiponectin and insulin-related parameters later in pregnancy would have helped 
confirming these speculations, as adiponectin secretion is expected to decrease with 
the increase in insulin resistance113.        
 In addition, maternal adiposity is another risk factor for the development of 
GDM, and provokes increased circulation of cytokines119,120,227. There was no 
correlation between gestational BMI and adiponectin level, possibly reflecting little 
change in inflammatory profile within the first trimester. Taken together, the 
potential role of adiponectin as an inflammatory marker and/or diabetogenic 
predictor from the first trimester of pregnancy was not conclusive. High CRP level 
is another commonly used marker of inflammation and is positively associated with 
increased GDM risk; however, it was not measured in this study288,289.  
 Gut flora dysbiosis is associated with pregnancy-related complications, 
such as insulin resistance, and nowadays, evidence supports strong involvement of 
dysbiosis of the gut in the pathogenesis of GDM151,153,154. Unlike with oral 
contraceptives long-term use, LBP level did not differ at 12 weeks between 
pregnant women who later developed GDM compared to those who did not. 
Possibly, the first trimester is too early to show LBP-related LPS or gut microflora 





were administered for a longer period. In addition, reduced microbiota richness was 
reported in the first trimester in those who later developed GDM132. The data from 
the presented IVF study is inconclusive in relation to the change in diversity of the 
microflora, since no stool samples were collected from participants, and reasoning 
of microbiota change is based on LBP, which in turn might not be sufficient to 
determine changes in gut microflora. Unlike previous studies showing a powerful 
positive correlation with obesity (independently predisposes to GDM) and negative 
correlation with insulin sensitivity117,230,290, LBP was not associated with any of 
these parameters in the presented study and hence could not predict insulin 
resistance and risk of GDM.       
 GDM-related inflammation and insulin resistance are also partially 
modulated by other placental hormones (refer to Section 2.3.2.1), including HPL, 
placental growth hormone, relaxin and kisspeptin89,291. Measurement of these 
hormones and any existing correlations with glucose homeostasis may have 
enriched findings of novel early biomarkers of GDM. Accelerated foetal growth 
(i.e. abdominal circumference) may precede the diagnosis of GDM. By the time the 
OGTT test is conducted (around 28 weeks of gestation), Sovio et al. suggested that 
foetal growth is already abnormal for those who are subsequently diagnosed with 
GDM292. Therefore, foetal development may also serve as an early predictor to 
GDM, highlighting the importance of close surveillance and earlier intervention. 
 Thus, the observed metabolic and endocrine changes, as well as 
inflammatory and gut microflora profiles were not distinguishable from a 
spontaneously-conceived pregnancy. This raises the question whether IVF-
conceived pregnancy should still be considered as a “high-risk” pregnancy. 
Preconception care increases the likelihood of a successful and healthy IVF-
conceived pregnancy, and may help identify conditions that have adverse effects 
on both mother and foetus. In addition, prenatal monitoring and surveillance of 
glucose and lipid metabolisms stratify pregnant women with higher risk and remain 
as key surrogates for early screening and diagnosis of GDM, especially for women 
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6.5. Pregnancy and Foetal Outcomes  
 
In single pregnancy, birth weight was within the references range of 2.5–
4.0 kg, but slightly below in multiple pregnancy (<2.5 kg for each of the babies)293. 
This finding is comparable to previous studies, which reported a higher birth weight 
in singleton preganncies57.         
 As mentioned earlier, caesarean section is more common in IVF-conceived 
pregnancies63 and even more in multiple pregnancies, which the latter is not 
considered as an indicator for a caesarean delivery294–296. Results from this study 
revealed similar findings, in which a significant association was found between 
twin pregnancies and delivering by caesarean section. In regards to babies’ weight, 
unlike in singleton pregnancy, first baby in twin pregnancy significantly predicted 
a caesarean delivery, and which remained significant even after adjusting for 
weight of mother at 12-week of gestation. In addition, caesarean section is usually 
recommended in foetal macrosomia (> 5.0 kg)295. Overall, babies’ birth weight did 
not exceed 4.0 kg in the present study, and this may suggests that birth weight of 
babies was not likely the only reason to undergo a caesarean section.  
In regards to mother’s characteristics and type of delivery, preconception 
obesity (BMI >29 kg/m2) and greater gestational weight gain (> 11 kg 
recommended by the Institute of Medicine in obese women), are documented to be 
associated with higher rate of caesarean delivery297. Preconception BMI and BMI 
at 12 weeks did not predict a caesarean section. Measuring late gestational weight 
gain may have provided more understanding on gestational weight gain and 
indication for a caesarean section. Advanced maternal age (≥ 35 years) relates to a 
higher rate of a caesarean delivery, possibly explained by the physician and 
pregnant women concerns over pregnancy outcome in older age298–301. The present 
study did not find any association between age of pregnant women (≤39 years) and 
a specific type of delivery. Furthermore, diabetes in pregnancy is associated with a 
higher rate of a caesarean delivery, partially to reduce the incidence of unexpected 
intrauterine death during delivery and foetal trauma related to macrosomia295. The 






Women from this study may have presented other obstetric complications 
or conditions (not reported in this study) that urged a caesarean section (e.g. 
repeated caesarean, failure to progress in natural labour, position of baby and cord 
prolapse)294,295, and less likely IVF or GDM-related. Another possible explanation 
for the high rate of caesarean section which was described earlier, is that women 
may consider IVF-conceived pregnancy as “precious” after many years of 
infertility and may have requested to have a delivery by elective caesarean section 
to prevent perceived complications and not necessarily clinically indicated64.  
 
6.6. Study Strengths and Limitations  
 
The main strength of this study consists of accessing information from a 
multicultural population. It is important to mention that this study is a prospective 
study where women are followed from baseline (including preconception 
assessment) to the first trimester. Consequently, assessment of the outcomes is 
better than basing it on a retrospective data. Repeated measures of glucose and 
insulin throughout the study have allowed assessing the effect of different 
exogenous hormones (FSH and LH, followed by oestrogen and progesterone). 
Estimates of GDM risks tested a wide range of well-documented factors and 
predictors simultaneously rather than measuring them only in isolation, and tested 
the possibility of novel markers. Adjusted for risk factors when assessing the 
biochemical potential predictors of GDM with a regression model.   
 There are several limitations to this study, including misreporting of 
participants ethnicity and history of GDM. Using HOMA-IR to estimate insulin 
sensitivity is not as precise as the euglycaemic clamp protocol, but it is certainly 
more practical and non-invasive for pregnant women. In the non-pregnant group, 
measuring anthropometrics (weight) and biomarkers at 4 weeks may have likely 
showed higher levels of glucose, insulin, lipids and thyroid profile than those 
reported in the results section at 12 weeks. In addition, measurement of oestrogen, 
progesterone levels, and FSH/LH ratio at 12 weeks may have allowed a better 





placental hormones at week 12, may have allowed observing early changes in 
glucose homeostasis (normally occurs mid-gestation) and identifying other possible 
novel markers of GDM. Dietary intake and stool sample collection would have 
enabled more accurate assessment of changes in microflora. The inclusion of a 
spontaneous-conceived pregnant group would have allowed comparing the usual 
gestational physiological changes compared to IVF-conceived pregnancy and the 
magnitude of change induced by IVF hormonal therapies on the different 
parameters. Finally, testing metabolic and endocrine parameters during mid-second 
trimester may have provided additional insight on GDM predictors. It will be also 
important to evaluate long-term effects of IVF hormones on foetal outcomes in case 
they are administered until delivery. Despite these limitations, the findings of this 






















































This thesis enriches the literature with insight on the safety of IVF hormonal 
therapies and their effect on maternal metabolic, endocrine and inflammatory 
status. IVF therapy induces some weight-gain and impairment in glucose, insulin 
and lipid homeostasis, but not to the extent of diabetogenic, atherogenic and 
inflammatory levels. IVF hormones combined with gestational hormones did not 
hasten or aggravate the metabolic, endocrine and inflammatory changes of 
pregnancy. Pregnancy masks the metabolic-related effects of IVF therapy, and 
instead normal gestational physiological adaptations become manifest during the 
first trimester with minimal changes in gut microflora. This may reassure IVF 
seekers of the safety of the IVF procedure, with comparison with a spontaneously-
conceived pregnancy, at least until the first trimester.   
Early prediction remains more promising than prevention of GDM, given 
that current measures are not yet powerful enough in preventing onset of GDM. 
Consequently, identifying preconception and early gestational markers of GDM are 
key preventive measures. A combination of preconception and prenatal metabolic, 
endocrine and inflammatory biomarkers enables a better estimation of GDM risk, 
until identification of optimal markers for subsequent GDM development. In 
addition to the well-documented preconception predictors of GDM development 
including higher BMI and advanced age, there should also be emphasis on ratio of 
FSH/LH. Weight gain during the first trimester and maternal BMI predicted GDM 
development. In relation to glucose-related GDM markers, early assessment of 
insulin level and sensitivity remain the best predictors of future change in glucose 
during later stages of pregnancy and onset of GDM. The exciting predictive role of 
gut microflora in GDM was uneventful during the first trimester of gestation. 
Prospective studies testing these biomarkers in mid-gestation will grant more 
information in relation to early pathogenesis of GDM.  
Preconception maternal characteristics (age and BMI) did not predict 
delivery by caesarean section, nor did prenatal BMI (at 12 weeks) and presence of 
GDM. In regards to foetal outcome, multiple pregnancies strongly correlated with 





pregnancies predicted this type of delivery. In this study, caesarean section was 
possibly urged by obstetric complications or more likely electively requested by the 
mother as a precaution of unpredicted complications harming her “precious” baby. 
Given the similarities between spontaneous and IVF-conceived pregnancy in 
regards to the normal physiological effect of pregnancy, this may ensure IVF 
pregnant women of the safety of a natural delivery, unless clinically indicated 
otherwise.  
 
7.2. Future Directions  
 
Findings from this study therefore provide new evidence, in relation to 
optimal preconception and preventive measures of IVF therapy, which can be 
considered for future updated guidelines. Firstly, monitoring of glucose, lipids and 
thyroid functioning during IVF therapy should be performed particularly with 
failed and repeated IVF attempts. Secondarily, in addition to the confirmed 
preconception cut-offs from this study (e.g. BMI and ratio FSH/LH), further 
updated preconception preventive measures and stratification of high-risk women 
are needed to manage controllable factors and prevent possible obstetric 
complications. Such measures will also improve IVF success rate, and both 
pregnancy and foetal outcomes. Furthermore, accurate GDM biomarkers will 
optimise screening and potentially reduce cost of unnecessary tests and 
implications of missing GDM cases. Finally, following participants post-delivery 
will convey with greater certainty longer-term impact of IVF hormones on mother 
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Effects of fertility drugs on glucose homeostasis, and 
other metabolic parameters on patients undergoing In 




































Cycle:          Regular                                                  Irregular 
 
 
History of GDM: 
 
 




 Blood Analysis 
Frequency Level/ Unit Type 
4 times  Fasting glucose 
4 times  Serum insulin 
Twice  Lipid profile 
4 times  FSH, LH 
4 times  Oestrogen, Progesterone 

















Appendix 5. Consent Form 
  
 
Informed Consent Form 
 
 
Project: Effects of fertility drugs on glucose homeostasis and other 
metabolic parameters on patients undergoing In Vitro Fertilisation 
(IVF) 
 
 وغيرها من ناالنسولي ومقاومة الجلوكوز على توازن اإلخصاب أدوية تأثير :دراسة مشروع
 االنابيب أطفال لعالج يخضعون الذين المرضى لدى األيضية المؤشرات
 
The United Arab Emirates (U.A.E) are listed among the top 10 countries worldwide 
in term of obesity and have one of the highest rates of polycystic ovary syndrome 
(PCOS), whereby 60 % of Gulf women and 30 % of Indian origins women living 
in the U.A.E have PCOS. Obesity has increased along with increasing related 
abnormalities in the reproductive system, such as an ovulation and infertility. In 
fact, 20% of couples worldwide are infertile; this corresponds to 50% of women in 
the UAE are facing infertility issues. Obesity is considered as a major risk factor 
for developing pregnancy-related complications such as gestational diabetes 
(GDM); as well as PCOS independently of the obesity factor. More scientific-based 
studies are required to assess whether Assisted Reproductive Technology (ART) is 
another predisposing factor to GDM compared to normal pregnancy. 
 
 أعلى ولديها السمنة حيث من العالم في األولى العشرة الدول بين من المتحدة العربية اإلمارات دولة وتعد
 الهنديات النساء ٪ من30و الخليجيات النساء ٪ من60نسبتها  تبلغ حيث المبايض تكيس متالزمة معدالت
 ذات تشوهات زيادة مع جنب إلى جنبا السمنة زادت المتحدة. وقد العربية اإلمارات في دولة  يعشن اللواتي
 يعانون العالم أنحاء جميع في أزواج 5من كل  1الواقع،  والعقم. في اإلباضة مثل التناسلي، الجهاز في الصلة
العقم.  تتعلق المتحدة حيث تواجه قضايا العربية اإلمارات دولة في النساء ٪ من50مع  يتوافق وهذا العقم، من
 عن المبايض وبشكل مستقل الحملي وكذلك تكيس السكري مرض لتطوير رئيسي خطر عامل السمنة تعتبر
 اإلنجاب على المساعدة التكنولوجيا كانت إذا ما لتقييم مطلوبة العلمية الدراسات من السمنة. المزيد عامل
 .الطبيعي الحمل مع بالمقارنة الحملي السكري لمرض آخر مؤهب عامل
 
You are being asked to participate in study of “Effects of fertility drugs on glucose 
homeostasis and other metabolic parameters on patients undergoing In Vitro 






االنسولين  ومقاومة الجلوكوز على توازن اإلخصاب  أدوية "تأثير دراسة مشروع في مدعوة للمشاركة فأنت
أن  المتوقع من حيث "االنابيب أطفال لعالج يخضعون الذين المرضى على األيضية المؤشرات وغيرها من
 .شخصا 192 المشاركين عدد يكون
This study will be done by: 
 
 :الدراسة هذه على القائمون 
 
• Dr. Hayder A. Hasan, principal 
investigator, College of Health 
Sciences, University of Sharjah 
 
• Dr. Marikinti Karunakar, Co-
investigator,  Fakih IVF 
 
• Mrs Ayla Coussa, Co-investigator,  
Fakih IVF 
 
الباحث  - حيدر عباس حسنالدكتور • 
 جامعة الرئسي، كلية العلوم الصحية،
 الشارقة 
 
 باحث، -كاروناكار ماريكينتيالدكتور •
 أطفال وعالج لإلخصاب فقيه مركز
 دبي في االنابيب
 
 فقيه مركز باحث، - كوسا آيال السيدة •




 Study Details  
 الدراسةتفاصيل 
As part of this study, the 
researchers will measure your: 
 




• Blood pressure 
 
 الطول  • 
 الوزن  •
 ضغط الدم  •
 
 
A blood sample will be collected from you at 4 episodes during your IVF treatment, 
which will be sent to a laboratory for the following tests: 
 المختبرية الفحوصات إلجراء المختبر إلى إرسالها وسيتم العالج، أثناء حلقات 4في  دمك من عينة اخذ يتمس
 :التالية
 
• Oral Glucose Tolerance 
Test (OGTT) 
 الجلوكوز تحمل اختبار • 
• Insulin level  • الدم  في مستوى األنسولين 
• Women hormonal levels  
• Lipid profile 
 الشهرية للدورة النساء هرمونات تحليل • 
 والحمل
 الدهون  معدل •
 
Neither the patients nor their medical insurances will be paying for these tests; but 
instead the ethic will be covering the costs of the tests. 
It will take around two hours to complete the tests at Fakih IVF Clinic in Dubai. 
There are no known risks to participate in the study and you may not benefit directly 
from taking part in this study. However, this study will help us assess if IVF drugs 





profile. The study will also help screening and managing patients who are more at 
risk of pregnancy-related complications.  
 
 ال وقد  معروفة  مخاطر توجد ال.دبي في لإلخصاب  فقيه مركز في االختبارات إلكمال ساعتين يستغرق وسوف •
 توضيح ما إذا على الدراسة هذه تساعدنا فقد ذلك، ومع  .في هذه الدراسة المشاركة من مباشر بشكل تستفيد
 الدهون. معدلو االنسولين ومقاومة الجلوكوز توازن األيضية المؤشرات على تأثير لها اإلخصاب أدوية كانت
 بالحمل.  المرتبطة  للمضاعفات عرضة أكثر هم الذين و رعاية المرضى فحص في أيضا الدراسة وستساعد
All the study information will be kept confidential. You will not be identified in 
any publication or presentation of the study findings. Only groups' results will be 
reported. Blood samples (with your Fakih IVF code) will be preserved and stored, 
and can be used in the future to test other parameters. Samples will also be locked 
and only accessible by the PI and co-investigators.                                                                              
All documents from this study will be kept confidential at Fakih IVF Clinic, 
locked with Dr Karunakar Marikinti (Tel: ), and only accessible by 
the co- investigators of the study.  
 
 هذه لنتائج عرض أو منشور أي  في عليكم التعرف ولن يتم .سرية الدراسة هذه معلومات جميع وستبقى •
الخاص بك(، ويمكن استخدامها في  IVFعينات الدم )مع رمز فقيه  سيتم حفظ وتخزين .الدراسة
 .مطالعتها من قبل الباحثون في الدراسة فقطالمستقبل الختبار معلمات أخرى. كما يمكن 
 ماريكينتيالدكتور مع سري بشكل بجميع الوثائق وسيتم االحتفاظ .فقط كمجموعات إبالغ النتائج وسيتم
ويمكن  دبي في االنابيب أطفال وعالج لإلخصاب فقيه مركز في  )هاتف:  (-كاروناكار
 .مطالعتها من قبل الباحثون في الدراسة فقط
Your decision whether or not to participate will not affect your current or future 
relationship with the investigator, nor your IVF treatment. If you decide to 
participate you are free to withdraw at any time without affecting this relationship. 
The researchers also may choose to withdraw you from this study if this is in your 
interest. 
 
 في  عالجك على أو الباحث مع المستقبلية أو الحالية   عالقتك يؤثرعلى لن سوف عدمه أو المشاركة قرار إن •
 .المركز
 للباحث يكون الخيار وقد العالقة هذه التأثيرعلى دون وقت في أي االنسحاب حر في فأنت المشاركة قررت إذا
 .مصلحتكم من ذلك كان إذا الدراسة هذه من بانسحابكم
 
You are encouraged to ask any questions regarding this project and if you wish to 
find out the results of this study you may contact Dr Karunakar Marikinti or Mrs 
Ayla Coussa (contact details above) at Fakih IVF Clinic in Dubai, six months from 
today. 
If for any ethical concern arises, you may contact the Dubai Scientific Research 
Ethics Committee directly (042191961/65) or by email (DSREC@dha.gov.ae). 
 
 عليك الدراسة هذه نتائج معرفة في ترغب كنت وإذا المشروع، هذا حول  سؤال أي لطرح مدعو أنت •
 مركز في  )أعاله تفصيل االتصال مذكورة (كوسا آيال السيدةأو كاروناكار ماريكينتيبالدكتور االتصال





أخالقيات في حال نشوء أي مخاوف أخالقية، يمكنك التواصل مع لجنة 




I understand that; 
a. My signature indicates that I 
voluntarily agree to be a part of this 
research study 
b. I will receive a copy of this form 
 :االتفاق وقيعت 
 بان؛ أتفهم أنا
 أن على طوعا أوافق أني إلى توقيعي يشير .أ
 البحثية الدراسة هذه جزءا من أكون
 النموذج هذا من نسخة على احصل وسوف .ب
 
Signature of Subject: 
 




Signature of Investigator: 
 
 الباحث: توقيع 
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